List of Biotech, Pharmaceutical & Life Sciences companies in Germany - 259

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S. patients annually, the first 30 days after diagnosis see persistently high mortality rates of 50-70%. Understand its pathophysiology, including the critical role of Dipeptidyl Peptidase 3, and the latest interventions.

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ® and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it has a broad network of distributors in more than 20 countries at the international level. aap Implantate AG is a stock listed company. Its share is quoted in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). .

AATec Medical GmbH is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The first product candidate is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections.

AaviGen GmbH is a biotechnology start-up located in Heidelberg, Germany. Our primary purpose is the development and commercialization of precision gene therapies for cardiovascular and cardiopulmonary diseases. Our business model builds on the success of the InoCard GmbH, a predecessor that was acquired by uniQure N.V. and subsequently entered into a development alliance with Bristol-Myers-Squibb. Please find our imprint ("Impressum") and data privavy statement ("Datenschutzerklärung") at https://aavigen.com/content/imprint.html and https://aavigen.com/content/privacy.html

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system's power specifically against cancer cells. Through viral replication within cancer cells, Abalos' arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos' goal is to achieve a quantum leap in immuno-oncology.

AB Enzymes is an industrial biotech company specialized in enzymes and their applications. The company is part of Associated British Foods and represented worldwide. Our offices are located in Brazil, China Germany, Finland, Singapore and USA. Our products range from food grade enzymes for baking and beverages, grains and vegetable oil seeds processing, to enzymes for animal feed and technical applications: pulp & paper, textiles and laundry detergents. We partner with our diverse and unique customers to support them in their process optimization needs.

Acandis GmbH is a medical technology company based in Pforzheim, Germany, founded in 2006. It focuses on developing, manufacturing, and marketing products for the treatment of neurovascular diseases, particularly in acute and preventive stroke treatment. The company is recognized for its innovative approach and has been named one of the TOP 100 most innovative SMEs in Germany multiple times. Acandis offers a variety of high-tech medical devices, including thrombectomy devices for removing blood clots, embolisation devices to block abnormal blood flow, stents to keep arteries open, and catheter systems for minimally invasive procedures. These products are developed in collaboration with healthcare professionals to ensure they meet clinical needs effectively. With a dedicated team of around 107 employees, Acandis aims to expand its reach internationally, providing essential tools for stroke prevention and therapy to endovascular specialists.

Acousia is a pioneer of novel medicines. Founded in 2012, the company’s experienced and entrepreneurial management team is committed to combating hearing loss. Thanks to its exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic and an ecosystem of experts and CROs, Acousia has made significant strides with its advanced small molecule drug candidates.

ActiTrexx GmbH is a new biotech start up and was founded in 2020. Our vision is to offer a curative cellular therapy to prevent inflammatory reactions in conditions like GvHD, solid organ transplantation and autoimmune diseases. Regulatory T cells (Treg) - natural guardian cells of the immune system - are the key players of our cell-based drug product. Isolated Treg are activated ex vivo via specific methods and administered to patients intravenously. Unlike other comparable approaches, activated Treg (ATreg) will not be expanded in vitro, protecting them against a possible loss of function. Thus, ATreg is a safe and efficient treatment option for transplanted patients preventing and providing substantial decrease of GvHD severity and related mortality as well. The founders of ActiTrexx GmbH combine many years of unique experience in basic research, biotechnology, clinical application and pharmaceutical development. The management team is supported and complemented by a strong network of collaborators, advisors and key opinion leaders as well as experienced managers.

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Enibarcimab is a first-in-class monoclonal antibody. Enibarcimab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Enibarcimab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.

Personalised therapies for the heart and vasculature Innovative, independent, close to the patient. We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has been successfully tested in two Phase II studies. We work closely together with excellent academic and clinical teams in basic and clinical research. We use state-of-the-art analytical methods, and we develop our products according to the highest quality standards (GLP, GMP and GCP). Revacept is a therapeutic agent for the prevention and treatment of acute arterial thrombosis, which can lead to heart attack, acute limb ischemia and stroke. A Phase II clinical trial in 160 patients with stroke or transient ischaemic attack (TIA) has been completed. It showed beneficial effects in patients treated with 120 milligrams (mg) of Revacept. Another Phase II clinical trial investigated Revacept in 332 patients with stable coronary artery disease (ISAR-PLASTER) has been completed. This study conducted by the German Centre for Cardiovascular Research (DZHK) confirmed the very good tolerability of Revacept. Overall, Revacept did not lead to increased bleeding despite of its additional platelet aggregation inhibition on top of conventional standard therapy. It decreased ischemic strokes in NMR and improved the net clinical benefit of MACE and bleeding. Recently, the FDA has approved the preclinical and clinical development and the further phase 3 protocol until market approval. Antibody therapeutic In collaboration with Morphosys an anti-GPVI Fab antibody has been discovered. The candidate is currently in preclinical evaluation for the treatment of acute coronary syndrome and stroke. Imprint: https://www.advancecor.de/imprint/ privacy policy: https://www.advancecor.de/privacy-policy/

We are a research-oriented provider of innovative, efficient products and services for early detection, diagnosis and prognosis of autoimmune and infectious diseases, allergies and food intolerances. We strive to improve the diagnosis and management of different diseases as a provider of innovative in-vitro diagnostic products that really work. Built on a tradition of innovation and an interdisciplinary knowledge network, AESKU.DIAGNOSTICS offers unique diagnostic options: faster, more efficient and reliable test systems designed to improve clinical outcomes for the benefit of patients and physicians. Follow us on our other Social Media Profiles. https://www.linkedin.com/company/dst-diagnostische-systeme-&-technologien-gmbh/about/ instagram: https://www.instagram.com/aesku.group/ Contact us: Website: www.aesku.com⁠ E-Mail: socialmedia@aesku.com⁠

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

AiCuris (from 'Anti-infective Cures'​) is a pharmaceutical company focused on the discovery, research and development of novel antiviral agents for the treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients. Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris has a broad and innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

Aix Scientifics is a Contract Research Organisation that specializes in planning, implementing, and evaluating clinical research for pharmaceutical products and medical devices.

Akribion Genomics discovers novel groundbreaking CRISPR nucleases and develops them into a new class of genetics-based cancer therapies and advanced genome editing tools. Akribion Genomics' flexible CRISPR-based gene editing technology platform features distinct technology families (G-dases®) with broad application in Industrial Biotechnology (and Agriculture), and offers a groundbreaking technological advantage for therapeutic and diagnostic solutions. Akribion Genomics is committed to using its technology with high ethical standards to improve products, processes and medical treatments. Our mission is to enable new treatment approaches in oncology by employing novel CRISPR technology that allows targeted cell depletion using RNA biomarkers. On top, we aim to provide access to advanced CRISPR genome editing technology with freedom-to-operate. All this is summarized in our motto and brand "Gediting". Akribion Genomics is a company in founding and soon-to-be spin-off of BRAIN Biotech AG, a renowned international group of companies providing innovative biobased products and solutions to industry.

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed. Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring additional applications in oncology, autoimmune diseases, fibrosis, and infectious diseases. The flexibility and broad potential of Akribion's technology makes it a promising platform for various therapeutic areas, as by simply changing the guide RNA, the technology can be quickly adapted to target different cells, making it much faster to develop new treatments compared to traditional methods. Founded in 2024 and based in Zwingenberg, Germany, Akribion was spun out of BRAIN Biotech AG, the specialist in biosolutions for industrial applications.

ALACRIS Theranostics GmbH is a Berlin-based systems medicine company founded in 2008, originating as a spin-off from the Max Planck Institute for Molecular Genetics. The company focuses on developing innovative solutions in healthcare, particularly in biomarker discovery, drug development, and precision medicine, with an emphasis on molecular oncology. The company offers comprehensive Next-Generation Sequencing (NGS) services that enhance precision medicine. By integrating advanced omics technologies with mechanistic computer modeling, ALACRIS develops biomarkers of drug response. Their services include high-dimensional data analytics and bioinformatics systems, tailored to meet medical needs in collaboration with clinicians. ALACRIS Theranostics is actively involved in partnerships with academia, biotechnology, and pharmaceutical companies, contributing to various research projects and applying their technologies in clinical settings. ALACRIS is committed to delivering data quickly while ensuring quality and confidentiality. Their interdisciplinary team combines expertise in sequencing technologies, advanced computing, and bioinformatics to provide effective healthcare solutions.

With over 30 years of experience, Alcedis combines medical expertise with ground-breaking technologies to pioneer data-driven clinical research. Our module-based service concept and flexible data capture systems adapt seamlessly to any project structure and accompany your entire research process - from Phase I to drug approval and beyond market access into real-world evidence.

Anbio Biotechnology (Anbio) is a leading global medical device company with a focus on in vitrodiagnostics. Our goal is to revolutionize the diagnostics market by personalizing and decentralizingcurrent diagnostic solutions, enabling rapid diagnosis and improving patient prognosis. Weachieve this by offering cutting-edge laboratory, wellness, at-home, and point-of-care (POCT) invitro diagnostic (lVD) solutions that are rapid, accessible, and affordable on a global scale. Since its establishment, Anbio has been committed to delivering the most advanced diagnosticsolutions while ensuring cost-effectiveness for our customers. Our extensive capabilities inresearch and development, manufacturing, and global product distribution logistics allowing us tocontinuously focus on cost reduction while offering a wide range of mature laboratory diagnosticsand point-of-care technology (POCT) products. Our product range spans across cancer, cardio.vascular conditions, pharmacogenomics, hormones, infectious diseases, inflammation, and drugsof abuse tests.

ANTITOXIN GmbH is a biotechnology company that specializes in producing Blood Typing Antisera and Rare Sera for various blood groups.

Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients.

Aptarion is dedicated to leveraging the strengths of biostable L-aptamers (highly specific "chemical antibodies") across the biomedical spectrum. Besides the discovery of new L-aptamers for the functionalization of sensors with its powerful platform technology, Aptarion pursues the development of its proprietary existing L-aptamers as therapeutics in areas of high medical need.

APURANO ist ein innovatives pharmazeutisches Unternehmen, das mit seiner weltweit patentierten Herstellungstechnologie PuranoTec® neuartige Nanoformulierungen entwickelt, die zur Behandlung verschiedener Krankheiten eingesetzt werden können. In 2023 führt APURANO die weltweit größten Phase III-Studien bei chronischen Schmerzen mit dem Arzneimittel Adezunap durch.

Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic' pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis. Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen. Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.

ARTCLINE GmbH develops innovative therapy methods for intensive care medicine based on immune cells. Our current main project is the development of the so-called ARTICE technology for the treatment of bacterial sepsis. ARTCLINE's vision is the development of innovative immune cell-based therapy approaches and to make the technology available to physicians and hospitals worldwide. The safety and effectiveness of the therapy is our top priority. Our extensive cell biological, clinical and industrial experience in the fields of immunology, sepsis diagnostics and therapy help us to realize our vision. Together with scientists and partners, we focus our research activities on the root causes and correlations of sepsis. For many years, the founders and the team of ARTCLINE GmbH have been successfully involved in the transfer of medical inventions from university research to industrial application. We have an extensive network and long standing experience in the development and successful marketing of medical devices and drugs.

ARTES Biotechnology is a globally working, well established and reliabletechnology provider for recombinant protein production. They develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ready-to-transfer processes for a wide range of products.

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company’s therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

ATLAS Biolabs is a leading European service provider of complex analyses in molecular genetics including next-generation sequencing and microarray services supplemented by high-level data analysis. In addition to the high standard and quality, a key benefit of using ATLAS Biolabs’ service portfolio is the close relationship that we build to our customers during project planning and realization. Our quality management is organized according to ISO 9001:2015.

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany.

To date, there are no approved drugs for the treatment of any sensorineural hearing loss disorder or tinnitus. At AudioCure Pharma we are determined to change this! Our vision is to turn incurable hearing loss into a treatable event. We are dedicated to the development of drug treatments for hearing disorders with a high unmet medical need. We have identified a new method of protecting and restoring the cellular key players that are critical to the hearing process. Therefore, our therapeutic approach goes beyond treating symptoms as we tackle the root cause of the disorders. Having successfully demonstrated preclinical proof of concept, our front-runner compound is currently in late stage preclinical development for the treatment of hearing loss. AudioCure is located in the vibrant capital of Germany, Berlin. Our offices are part of a cluster of high-tech companies and universities at the heart of the city. We are a team of highly skilled scientists and executives with a tight-knit network of academic partners, internationally renowned advisors and strategic investors. We also have close ties to the Charité University.

Axolabs specialises in a new class of drugs whose active ingredients are chemically derived from DNA or RNA. They are called oligonucleotide or nucleic acid therapeutics. We use our many years of expertise to help our clients make them a success. Some of these drugs have already been approved and are being used successfully against diseases that were previously untreatable in some cases. New drugs from this class are added every year. Axolabs is part of the LGC Group. Its business unit for nucleic acid therapeutics is combined under the brand name Axolabs. Axolabs operates companies in the following locations: Axolabs, Kulmbach, Germany Axolab Kulmbach GmbH, is the world's leading custom research organization in the field of nucleic acid therapeutics with a wide range of services. Axolabs Berlin, Berlin, Germany Axolabs Berlin is currently establishing a new site in Berlin for GMP manufacturing of nucleic acid therapeutics. The site will be dedicated to medium to large scale and early to late phase clinical GMP manufacturing of nucleic acid therapeutics. The state-of-the-art facility will deliver integrated analytical and manufacturing solutions. The operational start date is scheduled for 2024. Axolabs Petaluma, Petaluma, California, USA Axolabs operates a cGMP production facility in Petaluma for oligonucleotide compounds for technical, toxicological and preclinical to late-stage clinical trials. Services: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis.

At baseclick GmbH we believe that bioconjugation is not just a method to connect (bio)molecules, but a tool to develop valuable applications. So, a new strategy was needed: click chemistry! " Nobel Prize 2022, the basis of the baseclick patented nucleic acid modification technology". We are a dynamic, highly professional team and enabling life science researchers to overcome challenges and create better solutions in diagnostics, therapeutics, and vaccines development through our proprietary click chemistry. Our mission is to develop and provide the best nucleic acid labeling applications and reagents for the life science market. For further information please visit our website https://www.baseclick.eu/ https://www.baseclick.eu/our-vaccine-strategy-and-its-benefits/

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power. Our products help address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. In line with our mission “Bayer: Science For A Better Life,” we aim to improve people’s quality of life by preventing, alleviating or curing diseases. We also help provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. For these endeavors, we focus on developing and successfully commercializing innovative products and solutions based on scientific knowledge.

B. Braun is one of the world's leading medical technology companies. With over 65,000 employees, the family-owned company is a true partner, developing smart solutions and setting standards to drive advancements in health care. In 2022, the B. Braun Group generated sales of € 8.5 billion. You want to protect and improve the health of people around the world? Then you need a work environment that makes it easy for you to give your best. We bring together people in a collaborative culture. We encourage them to be open-minded, learn from each other and create new solutions together. In a time of rapid technological change, we constantly strive to enhance the solutions we provide. This is why we promote innovative ways of thinking and accountability. Imprint: https://www.bbraun.com/en/imprint.html Privacy Policy: https://www.bbraun.com/en/privacy-policy.html

BELANO - The Microbiome Company Die Erforschung des menschlichen Mikrobioms hat in den letzten Jahren zu wegweisenden Erkenntnissen geführt. Das Verständnis der Wechselwirkung zwischen Bakterienwelt um uns herum und unseren Körperfunktionen führt zu innovativen Therapieansätzen. Aus dieser Forschung sind bei BELANO mikrobiotische Wirkstoffe entstanden, die in Produkten in den Bereichen Derma & Kosmetik, Hals & Rachen, Mund & Magen und Wundversorgung & Hygiene eingesetzt werden.

Berlin Cures was first to follow up on the scientific finding that there are a large number of diseases associated with pathological functional autoantibodies directed against G protein-couples receptors. Heart failure and Long Covid belong to this group of diseases. Our aptamer BC 007 can neutralize these autoantibodies and this is the reason why Berlin Cures has been working for decades to develop a product based on scientific findings that may help many suffering patients.

Bicoll is an expert in bioactive plant-derived small molecules with outstanding expertise in high-tech natural product chemistry and validated experience in medicinal chemistry. Currently Bicoll focuses on two main fields such as neurodegenerative disorders (primarily, epilepsy) and longevity. In both of the fields it develops own preclinical candidates.

Bielefeld University is a Higher Education institution that provides academic programs and conducts research.

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.

BioEcho Life Sciences is a specialized solution provider for the extraction and analysis of nucleic acids. We create disruptive technologies, products, and workflows that make downstream processing of nucleic acids easier and faster, significantly increase throughput, and deliver reliable results. Our EchoLUTION technology enables the fastest DNA and RNA extraction on the market - in just one single step. It reduces the associated plastic consumption by up to 70 %. Customers in molecular diagnostics, academic and biopharmaceutical research, plant and animal breeding rely on our products: ready-to-use kits, high-throughput solutions for automation platforms, nucleic acid extraction services and process optimization for molecular biology laboratories. BioEcho, located in Cologne, Germany, was founded in 2016 by leading industry experts and is certified according to ISO 9001 and ISO 13485. During the pandemic, our Viral RNA/DNA Swab kit was used in up to 15 % of Covid PCR tests in Germany and 50 % of tests in Austria. Through our European direct Sales team, our global distributor network, and our international online shop we serve a worldwide growing customer base with best-in-class products and services. BioEcho. The Nucleic Acid Experts. Follow us on LinkedIn so that we can keep you posted and get in touch via contact@bioecho.de.

Biofidus is a privately held bioanalytical company based in Bielefeld, Germany, specializing in fast and reliable solutions to complex analytical challenges. Our highly qualified interdisciplinary team of experts in proteomics, metabolism, stem cell research, biochemistry, genetics, and biotechnology combines deep analytical knowledge to provide you with the best platform and guidance across a broad range of services. We offer a wide array of analytical and bioanalytical services focused on evaluating the structural and functional integrity of protein biologics, as well as cell and gene therapeutics, including: - Mass spectrometric assays - NGS sequencing (ONT) - Cell-based assays - Binding affinity assays - Spectroscopy - Chromatography At Biofidus, we help you define the right questions to accelerate and achieve your milestones efficiently, providing: - A single point of contact for streamlined communication - A comprehensive analytical portfolio - Unparalleled speed and quality Imprint: Biofidus AG Guetersloher Str. 54 33649 Bielefeld Germany +49 521 329 363 40 www.biofidus.de info@biofidus.de Management: Dr. Benjamin Müller, Dr. Heino Büntemeyer, Peter Spieth Chairman: Christof Schumann AG Bielefeld, HRB 41852 USt-ID: DE300823480

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin.

BioGenes is a full-service provider of customized immunoassay and antibody development, with a strong commitment to quality and service. Founded in 1992 and headquartered in Berlin, Germany, BioGenes is a recognized partner serving more than 600 customers in 40 countries. The company maintains long-term relationships with global pharmaceutical, biotech companies, CMOs and in vitro diagnostic firms. BioGenes provides highly customized solutions for the quality control of biological products, from drug discovery and drug development to the manufacturing of biologicals, as well as for diagnostic purposes.

 The company specializes in sophisticated custom monoclonal, polyclonal and anti-idiotypic antibody development and has a proven track record in the development, optimization, pre-validation and production of highly sensitive and robust ELISAs and host cell protein (HCP) assays. Furthermore, BioGenes offers the enhanced generic 360-HCP ELISA kits and supports customers with a comprehensive range of analytical services.

bio.logis is a digital genomics company starting as a spin-off from a genetic diagnostic laboratory setting. Our goal is to develop smart applications and functionalities to drive the implementation of genetic data into clinical decision making. For laboratories and hospitals, we provide highly innovative software solutions enabling automated interpretation, diagnostic reporting & delivery of genetic data. This supports patients and physicians at point of care in making informed decisions based on information derived from DNA. Our vision We want DNA owners to have easy and secure access to reliable health-related information based on their DNA. Our goal is to create a sustainable ecosystem, where all stakeholders contribute to and benefit from maximizing diagnostic quality, improving patient care and promoting research. Our background The bio.logis team consists of experienced human geneticists, scientists and IT experts. Building software solutions for complex medical tasks requires excellent software development expertise and a deep understanding of medical decision making processes. Our team has been formed with exactly this in mind: uniquely combining comprehensive genetic diagnostics knowledge and IT development expertise.

Biomax Informatics is a bioinformatics company that specializes in laboratory informatics and data analysis for research and development in the life sciences.

Contract Manufacturing & Analytical

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html

Devlope transfection products.

BIORON GmbH is a producer and worldwide acting trader of molecular biological and diagnostic products. Our main focus are ready-to-use solutions for professionals, i.e. high concentrated polymerases for lyophilisation.

Biotest is a specialist supplier of plasma proteins and biotherapeutic drugs used to treat diseases of the immune system or the haematopoietic system. The value chain of the medium-sized company, which was founded in 1946 as a family business, ranges from pre-clinical and clinical development to worldwide marketing. Biotest specialises primarily in the fields of clinical immunology, haematology as well as intensive care and emergency medicine. As the world market leader in hyperimmunoglobulins and the only manufacturer of IgM-enriched immunoglobulins, Biotest sees itself as an expert for innovative products for the prevention and therapy of life-threatening and rare infections. In addition, Biotest supports doctors and patients with coagulation factors that are also produced on the basis of human blood plasma. Among other things, the company has state-of-the-art plasmatic factor VIII and factor IX concentrates for the treatment of the congenital coagulation disorders haemophilia A and haemophilia B. Since 2019, the product portfolio also includes a first recombinant FVIII preparation from a human cell line. Biotest currently employs more than 2,000 people worldwide, the majority of whom are based at the company's headquarters in Dreieich near Frankfurt. The internationally active specialist supplier has subsidiaries in eight countries and sells its products in more than 80 countries. The plasma used is mainly obtained in the company's 22 plasma collection centres in Europe and meets the strictest official safety and quality requirements. Biotest manufactures all products exclusively in Germany.

BIOTYPE is an innovative German solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products & services for reliable analysis and interpretation of clinical biomarkers. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes IVD assays for clinical diagnostics and RUO assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD-compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-biomarker testing. MODAPLEX addresses the growing need to simplify and accelerate precision testing by reliably delivering actionable molecular information required for biomarker-guided care in precision medicine. The MODAPLEX consolidates multi-gene testing into one workflow with same-day results. BIOTYPE‘s quality management system is certified according to ISO 9001:2015 & ISO 13485:2016.

Your partner for the use of particularly sustainable and future-proof plastics in medical technology, pharmaceutical packaging and laboratory products. We help you to replace fossil-based plastics with renewable, recyclable and biologically safe materials. We supply you with the right materials for this purpose. With ISO 13485 quality management and tested biological safety in accordance with ISO 10993. Our broad network also supports you with upstream and downstream challenges such as the development and production of your sustainable medical, pharmaceutical or laboratory product.

Home of the BLINK Beads, the BLINK X and the BLINK One. BLINK is revolutionizing the field of bioanalytics and diagnostics. We have created next-generation microfluidics-free digital PCR technology that combines sample nucleic acid extraction, multiplex analysis and quantification in a single compact workflow. Our rapid, ultra-sensitive digital multiplex assays empower scientists and clinicians to make high-impact discoveries and enables rapid molecular diagnostics to achieve an immediate, targeted therapy, ultimately leading to better patient outcomes and a more effective healthcare system.

Booster Therapeutics is pioneering a new class of medicines that activate proteasomes (the cell’s natural quality control machinery) to treat a range of complex indications. The company is developing a multi-disease pipeline, with an initial focus on neurodegenerative diseases associated with impaired proteasome function.

Bosch Healthcare Solutions (BHCS) is a wholly owned subsidiary of Robert Bosch GmbH and was founded in 2015. We create innovative diagnostic solutions to improve people's quality of life and global healthcare. BHCS unites the innovative mindset of a young company with the leading expertise and quality claim of the Bosch brand. We tailor our products and services to the needs of our customers in order to continuously optimize the user experience. Our vision is to make healthcare routines a little better and easier every day. This motivates our interdisciplinary teams to pursue excellence. Corporate information: bosch-healthcare.com/en/corporate-information/ Privacy Policy: bosch-healthcare.com/en/data-privacy/

BRAIN Biotech AG is a leading European supplier of enzyme products, production strains and bioprocess solutions for more sustainable and efficient industrial processes. We focus on the fields of nutrition, health and environment. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into the segments BioProducts, BioScience and BioIncubator.

Breakpoint Therapeutics is developing targeted cancer therapies that modulate DNA damage response (DDR) pathways. Through precise interference with DNA repair, our drug candidates are designed to kill cancer cells without harming healthy cells. We leverage new insights and the concept of synthetic lethality to increase the therapeutic window and achieve better outcomes for patients with therapy-resistant and hard-to-treat cancers.

Capnopharm develops aerosol-based chemotherapies and immunotherapies for peritoneal and pleural cancer patients. Our science relies on a growing body of evidence around PIPAC™ (Pressurized Intraperitoneal Aerosol Chemotherapy), a minimally invasive aerosol drug delivery system. PIPAC™ provides numerous avenues for research and development in oncology – from re-formulation of existing chemotherapy drugs to next-generation drugs involving Nanoparticles, DNA, mRNA or Immunotherapeutics. Together with our pharmaceutical clients, we explore drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.

Cardiac Dimensions is reimagining the solutions available to patients suffering from heart failure (HF) by providing a therapy which allows patients to live longer, higher quality lives. Our product, the Carillon Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat patients with mitral valve insufficiency in a safe and effective manner. The Carillon therapy is the only indirect, no-touch mitral valve repair option designed to produce an annuloplasty effect while initiating left ventricular remodeling and improving long-term survival for patients. The Carillon therapy can also be used alongside other HF treatments should they be needed. Learn more about this proven solution for HF patients that uniquely treats the underlying causes—not symptoms—of mitral insufficiency at the website link below.

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

Our mission? To revolutionize the clinical research experience and empower researchers and healthcare professionals. At Carelane, we are driven by our desire to save our users time—time that can be redirected towards groundbreaking research and innovations. We believe that transforming the clinical trial process is not just necessary, but imperative for the future of healthcare.

CatalYm is a Germany-based biotechnology company that researches and develops gene therapies for the treatment of cancer.

We are a world leader in gene analyses for a wide range of medical, research and pharmaceutical applications. Since 2009, we have been helping doctors and patients find the genetic causes of rare diseases. We provide researchers and pharmaceutical companies with genetic analysis for clinical trials and medical innovation. We help oncologists and cancer patients find the best therapy option. We continue to drive science forward with our own insights. You can find our imprint under the following link: https://www.cegat.de/en/disclaimer/ Sie finden unser Impressum unter folgendem Link: https://www.cegat.de/impressum/

Cellbox Solutions is a young technology company focusing on delivering innovative and new solutions for the correct handling of living cells and biologic structures. Our product Cellbox is a self-sustaining carbon dioxide incubator supporting the appropriate storage, reproduction, transportation and analysis of biologic materials. The incubator's temperature and gas environment can be adjusted based on the biosphere necessary for the cultivating cells stored.

At Cellbricks, we are committed to make a significant impact on the lives of millions of patients dealing with compromised organ function. We achieve this through the innovative production of bioprinted tissue therapeutics, offering humans longer and healthier lives by restoring or supporting organ function. Cellbricks is a biotech company, combining world-leading expertise in synthetic biology and 3D-bioprinting. Leveraging our proprietary biofabrication technology and our tissue engineering proficiency, we are replicating human tissue at scale so researchers and doctors can provide patients with better clinical treatments. Our rapidly growing, multi-disciplinary team consists of biotech enthusiasts, scientists, PhDs, engineers, chemists and entrepreneurs from excellent universities and top companies from all over the world. Our labs and offices are located in Berlin, Europe's start-up capital. For inquiries please contact: Moritz Marschall mm@cellbricks.com

Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as prorietary serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world. As an ATMP developer and manufacturer we gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background we understand the high requirements our customers face during product development and the regulatory approval process. Sartorius CellGenix is headquartered in Freiburg, Germany.

CELLphenomics is a thriving and diverse place to work and learn. We offer fee-for-service research as well as research projects with academic partners on the local, national and EU level. Our partners, clients and staff, with representation from more than 20 countries, are brought together by the common goal of translational research.

Celonic is a "Pure Play" Biologics Contract Development Manufacturing Organization (CDMO). Celonic's mission is to help its customers, primarily small to large Biotech Companies, bring life-saving and improving drugs effectively to the market using innovative, "next generation" bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a state-of-the-art Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial GMP manufacturing facilities in Heidelberg, Germany. At present, more than 500 highly qualified employees work at Celonic. Due to the expansion of the company, Celonic is looking for committed and qualified employees. Our job is to make a difference!

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Cerca Biotech is a medical diagnostic company focused on bringing innovative solutions to oncology and women’s health. We strive to introduce the best tests to meet clinical needs at an affordable cost, with accuracy and rapid results at the core. Our focus is MammaTyper®, a reverse transcription-quantitative polymerase chain reaction PCR (RT-qPCR) assay and the first real innovation in breast cancer diagnostics for decades. MammaTyper® applies 21st century techniques to breast cancer subtyping, ensuring that every tissue sample is tested reliably, accurately, and quickly.

ChemCon GmbH - Your Good Manufacturing Partner! ChemCon is a contract development and manufacturing organization (CDMO) located in Freiburg, Germany. We manufacture drug substances (injectable, ophthalmic, oral, topic grade) and ultra-pure chemicals to your specifications. With multidisciplinary expertise we can meet your individual demands for small-molecule organic APIs, inorganic compounds, polymers, and highly potent or controlled substances. ChemCon’s facilities are optimized for the production of small to medium quantities (g to multi 100 kg per year). This is particularly interesting if you are sourcing APIs for clinical trials or commercial applications (i.e., orphan diseases, oncology, or emergency care) with a low annual demand. We also manufacture excipients, provocation substances, dietary trace elements, diagnostics, delivery agents, or reference standards. Your project will be under one roof from synthesis & process development/establishment all the way to commercial cGMP manufacturing, including full documentation, quality control and regulatory support. We also offer external analytical services, independent from production services. ChemCon looks back on an outstanding inspection history by both the FDA and European health authorities. Impressum: ChemCon GmbH, Engesserstr. 4b, 79108 Freiburg i.Br. Phone.: +49 (0)761-5597-0; E-Mail: Info@chemcon.com CEO/President: Dr. Raphael Vogler Commercial register: HRB 5973 Court of registration: Freiburg VAT Reg. No: DE812753447

CPL Sachse produces APIs for human and veterinary use. We manufacture APIs under cGMP for (pre-)clinical development and market supply up to ≤ 50 kg scale. The company has been successfully inspected multiple times by EMA (LaGeSo) and FDA. The following compounds are available from us under a GMP certificate from our local authority: - Anagrelide, - Atipamezole, - Clenbuterol (CEP), - Detomidine (CEP), - Medetomidine, - Methacetin(13C), - Nabilone - Phenoxybenzamine. Further APIs as well as reference standards for APIs and impurities are available on request. Moreover, we carry our route scouting for NCEs and develop and validate processes as well as analytical methods required to test the APIs and the subsequent drug products. Furthermore, we offer stability tests according to ICH guidelines. The company introduced and offers Maximator® HPE. This continuous high pressure extruder (HPE) allows rapid and reproducible large-scale production of unilamellar liposomes. Finally, we offer all regulatory services required for the preparation and submission of a pharmaceutical dossier (for APIs and drug products).

c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. c-LEcta is part of the Kerry Group.

CO.DON ist ein biopharmazeutisches Unternehmen und Hersteller von Zelltransplantaten. Mit mehr als 30 Jahren Erfahrung im Bereich Tissue Engineering liegt der Fokus auf der Entwicklung, Herstellung und Vermarktung von regenerativen, gelenkerhaltenden Zelltherapien zur Behandlung von Knorpeldefekten in Gelenken mit körpereigenen Zellen. Mission und Leidenschaft der Mitarbeiter:innen der CO.DON ist es, Patient:innen durch eine personalisierte Knorpelzelltherapie ein aktives Leben zu ermöglichen. Seit der ersten Behandlung im Jahr 1997, wurden mittlerweile über 19.000 Patient:innen mit den Produkten der CO.DON behandelt. CO.DON hat ihren Hauptsitz in Deutschland und ist darüber hinaus in den Niederlanden sowie mit Vertriebspartnerschaften in Österreich und Großbritannien tätig. In Einklang mit der Unternehmensvision arbeitet CO.DON aktiv daran ihr EU-weit zugelassenes Arzneimittel in weiteren Ländern Europas und damit mehr Patient:innen zugänglich zu machen. CO.DON ist ein Unternehmen der ReLive Biotechnologies. Das global agierende Biotechnologieunternehmen wurde 2021 mit dem Ziel gegründet, den Bereich der Biotechnologie und Zelltherapie nachhaltig zu beeinflussen und die Behandlung von orthopädischen und rekonstruktiven Erkrankungen zu revolutionieren.

At ColVisTec, we work with the world's leading manufacturers in the paint, pharmaceutical, plastics, and chemical industries. Our team of highly knowledgeable engineers and scientists support them with a reliable and industry-ready inline UV-Vis spectroscopy.​ ​ By adding inline UV-Vis spectrophotometry devices onto the assembly line, we can measure the production output in real-time. In addition, it opens fantastic opportunities for productivity as well as quality gains, leading to a huge stand-alone benefit for your factory when implemented into the context of digitalized manufacturing: Industry 4.0. Our technology can be customized for a wide variety of processes, allowing flexible hardware configurations, offering data output in different formats, and excellent integration with the software solutions already in place. We take pride in our extensive customer support and provide a full menu of training options to secure a smooth transition from off-line measurement to fully automated inline solutions. ​ From our headquarters in Berlin, Germany, we support our product line worldwide and work in close cooperation with other process machinery manufacturers to provide complete solutions when customers are in the market for new plants. Most often our technology is fitted to the existing manufacturing facilities, boosting their productivity and quality. We don’t see ourselves as suppliers of hardware, our aim is to provide unique solutions that are specifically required by your process. ​ Our company was founded in 2009 and is now co-funded by the Horizon 2020 program of the European Union.

Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions. The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.

Computomics was founded to bring the latest bioinformatics discoveries to industry application, facilitating global agricultural development.Crops: Parse large genomic data sets for plant breeders, deliver breeding recommendations, and provide molecular biology insight to reduce crop area requirements.Animal Health: Assemble and annotate genomic data from your species of interest, compare time-series data and visualize genomic variation in insightful ways.Metagenomics and Microbial Genomics: Analyze complex microbial communities and discover new organisms and metabolic pathways in a variety of samples.

CORAT develops phage-display derived fully human antibodies into passive vaccines to treat and to protect against COVID-19

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com

CRELUX, part of WuXi AppTec’s Research Service Division, is a global provider of structure based drug discovery solutions. We have been delivering customized and integrated services in drug discovery, X-ray crystallography, protein supply, biophysical analysis and fragment screening, to support small and large molecule, as well as biopharmaceutical drug discovery, for more than a decade. Our mission is to enable our clients to perform their work faster, more efficiently and more successfully. Integrating the comprehensive portfolio of services offered by our parent company WuXi AppTec, CRELUX offers a unique opportunity for our collaborators to accelerate discovery activities. Imprint: CRELUX GmbH Am KIopferspitz 19a 82152 Martinsried Germany www.crelux.com crelux_info@wuxiapptec.com VAT: DE242220245 Amtsgericht München HRB 165552 Managing Directors: Dr. Alex Satz, Dr. Thomas Meins

CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI's focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com

Founded in 2007, Curetis is a molecular diagnostics company whose mission is on the development and commercialization of reliable, fast and cost-effective syndromic testing products for the diagnosis of severe infectious diseases. The diagnostic solution Unyvero of Curetis enables rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with the conventional techniques. The Unyvero diagnostic platform can be used for the diagnosis of hospitalized patients with several applications with the broadest panels to detect pathogens as the HPN (Hospitalized Pneumonia), BCU (Blood Culture Infection), ITI (Implant & Tissue Infections), IAI (Intra-Abdominal Infections) and UTI (Urinary Tract Infections). The company is based in Holzgerlingen near Stuttgart, Germany and all the products are fully developed and produced in Germany. Curetis has entered into several international distribution agreements covering many countries across Europe, USA, the Middle East and Asia. Imprint: http://www.curetis.com/en/impress.html

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

Analytik Jena is a leading global supplier of analytical measurement technology in the field of molecular biology as well as liquid handling and automation technology. Whether in the fields of chemistry, pharmaceuticals, medicine and life science, food safety, agriculture or environmental analysis - Analytik Jena offers standard-compliant applications for routine analysis as well as for special tasks. Precision, reliability, easy handling and comprehensive service are the top priorities in the development of laboratory analysis products. Analytik Jena is part of the Swiss Endress+Hauser Group. Visit our YouTube profile for moving footage >>> https://www.youtube.com/@analytik-jena

We at CYTENA strive to empower our customers to serve patients faster and better. To accelerate workflows and bring new insights into biotherapeutic drug development, we provide precise control of individual cells through automation and microtechnology. Our instruments offer automated isolation of single cells with assurance of clonality and selection based on cell morphology. We can isolate many common cell types including bacteria. Our high viability rates make our instruments compatible with cell line development, single cell analysis, and other downstream applications. Most of the top ten largest pharmaceutical companies have successfully integrated cytena instruments into their workflows to quickly produce monoclonal cell lines for antibody development with minimal risk of cross-contamination. cytena instruments are also used for academic research for various topics including cancer, autoimmune disease and genomic research. Our instruments provide many benefits including: Assurance of clonality Every single cell isolated is imaged to provide assurance of clonality. The image sequence is assigned to the well of the deposited cell and stored for documentation. Viability Our instruments gentle handling routinely achieves high cell viability without the need for cell labelling. Purity A disposable cartridge is the only component in contact with the cells ensuring no cross-contamination between samples and no cleaning routines. Easy to use and flexible Our instruments and software are intuitive, user friendly, and can be readily implemented into existing structures and workflows. Interested in joining our team? cytena is a young, dynamic and highly motivated team. We are looking for new team members who also have interest in developing new and innovative products. Feel free to contact us if you have any inquiries on current open positions.

DeepEn offers hair-thin endomicroscopy solutions capable of subcellular resolution and high-speed observations within hard-to-access body regions. Our minimally invasive devices are used in research and diagnostics, helping to advance our understanding of diseases and microscopic processes deep inside sensitive tissues in real time. DeepEn was founded in 2024 as a spinoff from the Department for Holographic Endoscopy, led by Prof Dr Tomas Cizmar at Leibniz Institute of Photonic Technology in Jena, Germany. Our Managing Director is Dr Sergey Turtaev.

Devyser. A new level of certainty We’re specialists when it comes to diagnostic kits for complex DNA testing within oncology, hereditary diseases and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products.

Awarded for "most innovative German startup" from German business magazine Bilanz, DiaMonTech has developed a medical device that non-invasively measures your blood glucose without finger pricking, a drop of blood, or a test strip. Simply relax your fingertip on the sensor, wait 5 to 15 seconds, and your blood glucose level will be displayed. Our patented technology works with an invisible infrared light beam that looks into your skin and counts glucose molecules. Diabetes is a global challenge. More than 400 million people worldwide suffer from the disease. Our goal is to make checking your blood glucose level as easy as unlocking your phone. You will be able to get measurements throughout the day without pain or extra costs. Diabetologists suggest that more frequent blood glucose measurements can lead to better overall diabetes management and less diabetes-related illnesses. Until there's a cure for diabetes, DiaMonTech can make living with it much easier.

Choosing Quality. DiaSys Diagnostic Systems emerged as pioneer in the field of liquid stable reagents and has developed to an established provider of diagnostic solutions for the clinical laboratory. DiaSys develops, manufactures and markets diagnostic systems of superior quality. Laboratories, hospitals, and physicians in more than 100 countries rely on DiaSys products and services for the well-being of their patients. Since its foundation in 1991, the independent company has introduced more than ninety liquid-stable reagents for routine and special diagnostics completed by calibrators and controls. The instrumentation portfolio comprises partially and fully automated analyzers for small and medium-sized laboratories. Additionally, DiaSys provides devices and rapid tests for the point of care. Permanent update of quality products and processes and tailor-made solutions along with strong customer support maintain and extend DiaSys’ position as top quality supplier. In order to be close to the customer, DiaSys is continuously extending its global sales and support network; discover DiaSys’ activities all over the world. Impressum: https://www.diasys-diagnostics.com/misc/legal-notice/ Privacy Policy https://www.diasys-diagnostics.com/misc/privacy-policy/

Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation"). By optimizing bioprocesses and growth conditions, the company is not only increasing their clients' R&D efficiency but alsodramatically improving bioproduction outcomes such as yield, cost efficiency, and product quality.

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

The Eckert & Ziegler Group is one of the world's largest providers of isotope technology for medical, scientific and industrial use. The core businesses of the Group are: cancer therapy, industrial radiometry and nuclear-medical imaging. The two business segments are Medical and Isotope Products.

Eisbach Bio is an innovative start-up in biotechnology founded in 2019 as a spin-out of the Biomedical Center Munich. We are developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes. Eisbach will beat cancer at its own game.

Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential.

Epigenomics is a molecular diagnostics company focused on the development of blood-based DNA methylation tests for the early the detection of cancer. The Epi proColon test has recently become the first and only FDA approved blood test for colorectal cancer screening. Epi proColon, HCCBloodTest, and the Epi proLung tests are available in Europe as CE-marked IVDs. Industry partners, as well as the medical and life science communities, can access our expansive intellectual property portfolio. Epigenomics has been granted over 60 patents, in addition to many others that have been filed. These patents cover DNA methylation technologies and biomarkers, as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.

Eppendorf is a leading life science company that develops and sells instruments, consumables, and services for liquid-, sample-, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO2 incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, test tubes, microtiter plates, and disposable bioreactors complement the range of highest-quality premium products. Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also aimed at clinical and environmental analysis laboratories, forensics, and industrial laboratories performing process analysis, production, and quality assurance. Eppendorf was founded in Hamburg, Germany in 1945 and has about 5000 employees worldwide. The company has subsidiaries in 33 countries and is represented in all other markets by distributors. Imprint: www.eppendorf.com/imprint

As a family-owned and operated business, Erbe develops, manufactures,and markets systems for professional use in various medical disciplines all over the world. Since the company's foundation, Erbe has continuously reshaped and adapted its business to an ever-changing reality in several key disciplines such as gastroenterology, general surgery, gynecology, pulmonology and urology. The portfolio comprises devices and instruments for electrosurgery, vessel sealing, plasma surgery, cryosurgery, hydrosurgery, and imaging. Over the last ten years, sales have increased by 75% with an 85% increase in employees to over 1.800 colleagues worldwide. Today, the international group of companies is represented in 110 countries around the world with sales and service units, sales and production units and an international distributor network. A dedicated team of around 260 employees works intensively in research and development. Close cooperation with renowned physicians from medical faculties and hospitals is a key success factor that helps Erbe to successfully drive medical development forward Imprint: https://de.erbe-med.com/de-en/meta-navigation/imprint/ Disclaimer: https://erbe-med.com/fileadmin/pdf/company/Terms_of_use_EN.pdf

EUROIMMUN'un uzmanlık alanı immünoloji, hücre biyolojisi, histoloji, biyokimya ve moleküler biyolojidir. Otoimmün ve enfeksiyöz hastalıkların, alerjilerin ve gen analizlerinin laboratuvar tanısı için test sistemleri üretir. Hasta numunelerinde antikorların tespiti için test sistemleri ön planda olmakla birlikte, antijenler ve genetik markerlar da mevcuttur. Bunlar, indirekt immünofloresan, mikrotitreli ELISA'lar ve farklı blot teknikleri (Westernblot, EUROASSAY, EUROLINE, EUROLINE-WB) ve moleküler biyolojik (mikroarray) teknikler gibi immünohisto-kimyasal ve biyokimyasal yöntemlere dayanmaktadır. EUROIMMUN üretimini, dünya çapında patentleri taşıyan modern, son teknoloji prosedürleri ve mikroanaliz tekniklerine dayandırır. Şirket, tıbbi laboratuar teşhis ürünlerinin lider üreticilerinden biridir. Ürünlerimiz Avrupa, Amerika, Asya, Avustralya ve Afrika'da yaklaşık 130 ülkede kullanılmaktadır.   Aralık 2017 itibariyle, Amerikan PerkinElmer firması, EUROIMMUN hisselerinin çoğunluğunu elinde tutmaktadır. PerkinElmer medikal ve biyoteknoloji alanında uluslararası bir liderdir. Yenilikçi tespit ve görüntüleme teknikleri ve IT sistemleri ile, teşhis, tıbbi araştırma, çevre ve gıda analizlerinde kapsamlı uzmanlık sağlar.

What we do: we supply therapeutic molecules of clinical-grade quality for R&D and early drug development. Our solution: we repackage pharmaceuticals. So, we offer aliquots of clinical-grade mAbs, bs-mAbs, fusion proteins, ADCs, and other biologics as laboratory consumables. As an additional service, we provide analytical data to accompany each aliquot. Your advantage: you can order therapeutic molecules in clinical-grade quality as research consumables. Fast . Easy. Cost efficient.

Evonik is one of the world’s leading specialty chemicals companies. While we don’t produce electric cars, aircraft, medications or 3D printers, Evonik is part and parcel of these and many other end products. That’s because we contribute the small things that make a big difference. We make electric car batteries perform better, aircraft greener, medications more effective and 3D printers more efficient. In short: We think beyond the bounds of chemistry to make the world a better place. Today and tomorrow. We are an international group with a workforce of over 32,000 people spread across more than one hundred locations. Our daily work is shaped by global concerns, such as sustainability, diversity and digitalization. In all our business decisions, we take the present and future generations into consideration. After all, being ready for tomorrow is our business. Interested in joining our global team? Our wide range of opportunities extends from creative and innovative research through international management all the way to production. Whether you’re studying, starting out in your career or a seasoned professional, come help us make the world a better place. For more information about careers at Evonik, go to: www.careers.evonik.com. #HumanChemistry Find our netiquette on: www.evonik.com/netiquette

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

Who we are Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207 About Biosimilars: Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion. Contact: Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 info@formycon.com

Fraunhofer is EuropeÕs largest application-oriented research organization. Our research efforts are geared entirely to peopleÕs needs: health, security, communication, energy and the environment. As a result, the work undertaken by our researchers and developers has a significant impact on peopleÕs lives. We are creative. We shape technology. We design products. We improve methods and techniques. We open up new vistas. In short, we forge the future.

FundaMental Pharma - We are an early stage start-up company having laid the foundation for the development of a class of neuroprotective small molecules with an entirely new pharmacological mode of action. FMP neuroprotectiva are expected to be broadly applicable in the treatment of currently untreatable human neurological conditions. These include vascular brain damage and dementia, traumatic brain injury, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Huntington’s disease (HD), retina degeneration, and brain damage caused by virus or parasite infections.

Over 700 doctors and scientists from 35 establishments collaborate at the German Center for Infection Research (DZIF), jointly developing new approaches to prevent, diagnose and treat infectious diseases. This synergistic alliance of universities, hospitals and research institutions has established a globally unique infrastructure—aiming to effectively translate research results from bench to bedside, and vice versa: applying insights from clinical practice to research.

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. We combine expertise in glycobiology and know-how in antibody development to advance first-in-class antibody-based therapeutics for (immuno)-oncology. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins. Glycotope has to date discovered in excess of 200 GlycoTargets with several antibodies against selected targets under development.

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America and the US. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of € 1.8 bn. More Information on www.grunenthal.com Jobs & Career: http://careers.grunenthal.com/ Imprint: https://www.grunenthal.com/en/footer-links/imprint Privacy: https://www.grunenthal.com/en/footer-links/privacy-statement-social-media This company profile is managed by Global Communications. In our commitment to transparency and the principles outlined in our digital ethics charter, Grünenthal wishes to inform you that generative artificial intelligence technologies are occasionally used to enhance content on this channel. Each content piece has been reviewed and edited by a team member before publication to ensure accuracy.

Hain Lifescience GmbH is a manufacturer and distributor of in-vitro diagnostics based in Nehren in the district of Tübingen.

The company deliverscustom-designed applications and software solutions as well as sophisticated accessories forautomation projects.

Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Former clinical assets MESUPRON® and REDECTANE® have been partnered. Our mission is to research and develop therapies for cancer patients enabling them to receive a targeted and tailor-made course of treatment that is both highly effective and as well-tolerated as possible.

More than six hundred years ago, the first German university was founded in Heidelberg. Today, it attracts international acclaim for its life sciences – especially for medicine. As one of Europe’s largest and most modern medical centers, Heidelberg University Hospital’s 46 specialist departments offer medical care of the highest international standards in all areas of specialty with a focus on oncology care and on other diseases that require complex treatments. Heidelberg University Hospital’s active collaboration with national research facilities attracts patients from many countries worldwide.

Heinrich Heine University Düsseldorf is a Higher Education institution that offers a wide range of academic programs and research opportunities.

HepaRegeniX GmbH is a clinical-stage biotechnology company developing novel therapies for the treatment of acute and chronic liver diseases.

Heraeus is a family-owned global technology group headquartered in Hanau, Germany. The company's roots go back to a family pharmacy started in 1660. With its expertise and resources, Heraeus has been making meaningful contributions over generations and is committed to do so in the future. Today, the group bundles diverse activities in four Business Platforms: Metals and Recycling, Healthcare, Semiconductor and Electronics, as well as Industrials. Customers benefit from innovative technologies and solutions based on broad materials knowledge and technological leadership. In the 2023 financial year, the group generated revenues of €25.6 billion (US$27.7 billion*) with approximately 16,400 employees in 40 countries. Heraeus is one of the top 10 familyowned companies in Germany.

HMNC Brain Health - We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

Hummingbird extracts deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood. This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases.

IDT Biologika is your full-service CDMO for viral vaccines, cell & gene therapeutics and other biologics protecting humans worldwide! We are committed to your development and manufacturing needs from the early stages of process development to clinical trial materials and commercial manufacturing: • Process Development • Clinical & Commercial Scale Drug Substance (e.g. Viral Vaccines, Viral Vectors for Cell and Gene Therapeutics) • Aseptic Liquid Filling & Lyophilization (Biologics) • Labeling, Packaging & Storage • Quality Control and Analytical Services With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply: • FDA, EMA, ANVISA standards European and North American Footprint IDT Biologika is headquartered in Germany (Dessau-Rosslau and Magdeburg in Saxony-Anhalt). Here we operate one of Europe's premier integrated biopharmaceutical facilities for end-to-end services: • Process Development • Clinical Phases I-III • Commercial Scale Drug Substance (e.g. Viral Vaccines, Viral Vectors for Cell and Gene Therapeutics) • Commercial Manufacturing • Aseptic Liquid Filling & Lyophilization (Biologics) • Labeling, Packaging & Storage • Quality Control and Analytical Services Our North American facility is in Rockville, Maryland. The site has a long history of contract manufacturing and state-of-the-art technologies used to develop and manufacture clinical trial materials for phases I–II: • Process Development • Clinical-Scale Drug Substance (Viral Vaccines, Viral Vectors for Cell & Gene Therapeutics) • Aseptic Liquid Filling & Lyophilization • Packaging & Storage • Analytical Service

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in Tubingen, Germany.

Immundiagnostik – Closing the Gaps in Laboratory Diagnostics Immundiagnostik AG, founded in 1986, is a globally operating diagnostics company represented in over 30 countries. We focus on the development and production of innovative immunoassays (ELISA, EIA) and other analytical detection methods (e.g. HPLC and PCR) for medical routine and research. Furthermore, we offer a broad portfolio of antibodies and antigens. Our business relations include contract analyses for diagnostic laboratories and academic research institutions, esp. in context with clinical trials. Multiple cooperations with the pharmaceutical industry and a tight network with scientific organisations are the basis of a successful product development. Securing progress: Our comprehensive range of products is continuously refuelled by a rich pipeline of proprietary developments. With a headcount of more than 50 employees, Immundiagnostik's headquarter is located in Bensheim, south-western Germany.

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com

Inovedis stands for innovation in medical technology. As insiders, we know the issues that affect doctors and patients in everyday clinical practice. Our new innovation, SINEFIX™, came about because we wanted to improve the prevailing surgical method for refixation of the rotator cuff. And we have succeeded in doing that: For the first time, our PEEK implant creates a planar and stable connection between tendon and bone - and we assume that SINEFIX™ enables optimal healing. This saves time and money, for the doctors as well as their patients. In this way, we also position our products as an asset for the healthcare sector, which has to counter increasing cost pressure.

Insempra is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products. For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet's limited resources. That's why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature. Led by a hand-picked team of biologists, technologists and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future. To learn more about Insempra click the link in our bio to visit our website. We are committed to driving the regenerative revolution to manufacture at scale in collaboration with nature.

InspireMD is a commercial-stage medical device company with proprietary and innovative stent designs with integrated embolic prevention systems (EPS) designed for delivering neurovascular protection and stroke prevention. InspireMD is dedicated to the development of advanced technologies and seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes through a proprietary stent platform, CGuard™ EPS. CGuard brings to the world the only carotid stent platform with patented MicroNet™ mesh technology designed to reduce stroke during and after CAS. InspireMD (NSPR) is traded on NASDQ Capital Markets.

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development.

Isarna Therapeutics is a clinical stage biotech company, headquartered in Munich, Germany. Isarna develops ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in the pathogenesis of retinal disease. Current therapies – approved and pipeline products – mostly target the edema, with several anti-VEGFs approved or in development offering only minor improvements over current SOC. While anti-VEGF is a very effective therapy – it does not stop the disease progression of retinal pathologies like w AMD. Patients progress to late-stage disease despite effective anti-edema therapy – and thus develop fibrosis. TGF-b is a key driver of fibrosis, so blocking the production of this molecule intracellularly, using elaborated antisense molecules, promises to be a game-changer in retina therapy. Animal data show comparable efficacy of ISTH0036 to block neovascularization as anti-VEGF – with the added benefit of suppressing fibrosis. This MOA could be an effective long-term treatment in several retinal pathologies including the blockbuster-indications wAMD, DME, RVO, with a significant upward potential in dry AMD. A Phase 1 study showed excellent safety, Isarna Therapeutics is currently preparing a Phase 2a study in wet AMD and in DME/DR. Isarna is led by a highly experienced management, the COO, Rene Rückert, MD, MBA led at Bayer/Novartis the global development of both approved blockbuster drugs for retinal diseases – Eylea and Lucentis. The CMO, Prof. Marion Munk, MD, PhD is a leading global retina specialist. Isarna is open to discuss future partnering for the development and is seeking investors to finance the clinical development and growth of the company.

PASSION FOR PRECISION. ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information please visit: www.itm-radiopharma.com. Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines

joimax® is the leading developer and marketer of complete systems for endoscopic minimally invasive spinal surgery. With TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® Facet (e.g. for treatment of facet joints) and MultiZYTE® Sacroiliac (for treatment of Sacroiliac Joint Syndrome) or with EndoLIF® and Percusys® Plus for minimally-invasive endoscopic assisted stabilizations, proven endoscopic systems are provided that, together, cover a variety of indications. The smart electromagnetic Navigation system Intracs®em ensures the easy and safe access to any spinal target. In procedures for herniated disc, stenosis, pain therapy or spinal stabilization treatment, surgeons utilize joimax® technologies to operate through small incisions – under local or general anesthetic – via tissue and muscle-sparing corridors through natural openings into the spinal canal (e.g. intervertebral foramen, the "Kambin triangle").

We are the Peptide Experts! JPT has a large peptide synthesis capacity, providing over 1 million peptides per year. We offer all possible peptide modifications such as macrocyclic peptides, phosphorylated peptides, labeled and tagged peptides, radioligands, isotope labeling and more. Made in Germany Global Support More than 20 Years of Expertise Ethical, Environmental & Health Standards Portfolio: Custom Peptides Our patented technologies in peptide libraries, pools, microarrays, and micro-scale synthesis set us apart as a leader in the field. From micro to large-scale synthesis, our state-of-the-art labs in Germany deliver peptides tailored to your needs. Modified Peptides We produce modified peptides such as long and stapled peptides, dyes, labeled and biotinylated peptides, PTMs, unique building blocks, conjugations, macrocyclic peptides and more. PepMix Peptide Pools Peptide pools for antigen-specific T-cell stimulation in immune monitoring, assay control, cell therapy development, T-cell expansion etc. In addition to custom PepMix peptide pools we have more than 500 PepMixes in stock, for example: Control Pools: CEFX, CEF, Actin, CMV pp65 … Viral Proteins of EBV, SARS-CoV-2, CMV, VZV, HPV … TAA: Prame, NY-ESO-1, MART-1, MAGE A … Clinical Peptides & Pools Our resulting Clinical Grade Peptides have been approved for a variety of clinical applications including immunotherapy and vaccine development, immune monitoring, and clinical proteomics. Please visit our website for more information! JPT Peptide Technologies GmbH Management: Aurélien Claeyssen, Jens Holstein, Dr. Sierk Poetting Volmerstr. 5 D- 12489 Berlin T: +49 30 6392 5500 peptide@jpt.com https://www.jpt.com/ Registration Court: Berlin / Amtsgericht Charlottenburg, HRB 92692 VAT identification number: DE 814044483 Imprint: https://www.jpt.com/support-contact/corporate/imprint/ Privacy Policy: https://www.jpt.com/support-contact/corporate/privacy-policy/

Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.

Therapeutic peptides with pristine safety against psychiatric and metabolic diseases and computational engine to cost-efficiently generate novel peptides for a wide range of indications.

Your partner for nucleic acid extraction, biobanking, genotyping, epigenetics, transcriptomics, NGS, proteomics and bioinformatics.

Lifespin GmbH, a deep data company developing a proprietary AI-based health testing platform to measure quantitative metabolic data in patient samples. Our platform is based on mapping metabolomics for human health and translating that data into health information that can be deployed in a wide range of pharmaceutical, research, and clinical settings. Lifespin's health diagnostics software will be applicable in the broader healthcare space ranging from diagnostics to patient stratification and personalized medicine, as well as supporting the drug discovery process.

Lindis Biotech, Munich, is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies.

Lindt & Sprungli is recognized as a leader in the market for premium quality chocolate, offering a large selection of products in more than 120 countries around the world. During 170 years of Lindt & Sprungli's existence, it has become known as one of the most innovative and creative companies making premium chocolate.

LTS Lohmann Therapie-Systeme AG is a global pharmaceutical technology company based in Andernach, Germany. It specializes in non-invasive drug delivery systems and operates across three continents. LTS is a leader in transdermal and oral drug delivery, partnering with pharmaceutical companies to provide comprehensive solutions from concept to commercialization. The company employs over 1,000 people and has a significant manufacturing footprint, producing nearly a billion systems annually in its facilities in Germany and the U.S. LTS offers a range of services, including research and development, manufacturing, and lifecycle management. Its core products include Transdermal Therapeutic Systems (TTS) for precise drug delivery through the skin, Oral Thin Films (OTF) for dissolvable medication delivery, and Micro Array Patches (MAP) for intradermal delivery of biologics and vaccines. The company is recognized for its regulatory expertise and collaborates closely with clients to enhance patient compliance and therapeutic outcomes.

MACHEREY-NAGEL was founded in 1911 in Düren as a specialist manufacturer of filter papers. Since that time, we have evolved into an innovative international company for chemical and biomolecular analysis. • Family-owned in the 4th generation • More than 700 employees • 5 sites in Düren • Subsidiaries in Germany, Switzerland, France and the U.S. • Worldwide sales in 150 countries • More than 25,000 products MACHEREY-NAGEL stands for innovative and creative solutions which we have a penchant for developing in-house. In addition to the "traditional" departments, such as research, production, sales and media design, we also have departments such as mechanical engineering and device development as well as our own joinery. Our products are among the world's most reliable analytical systems. They are used, for example, in industry, healthcare, biotechnology, environmental analysis and research. Numerous patents and international certifications underscore the high quality of our products and the competence of our employees.

Mainz Biomed (NASDAQ: MYNZ) was founded in Germany and is becoming a leading molecular genetic diagnostics company developing market-ready molecular genetic diagnostic solutions. The company's goal is to place effective solutions in the hands of those who need them, with a focus on medical revolutions in diagnostic technology. Mainz Biomed offers genetic and genomic tests that identify the unique genetic profile of individual patients, as well as in-vitro diagnostic tests for the early detection of cancer in the United States.

Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss

The Max Planck Institute of Quantum Optics is a forefront research organizations in the fields of quantum physics and photonics, with light-matter interaction at its core. In five different research areas excellent scientists from all corners of the world are working together in an open and diverse environment, breaking the ground to what could become another revolution in science. Our laboratories are amongst the best equipped in the world and our scientific culture and spirit is based on freedom and trust, both allowing our scientists to reach the most ambitious objectives.

We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.

MedGenesis Therapeutix (MedGenesis) is a privately-held biopharmaceutical company committed to developing and commercializing highly innovative treatments for patients with serious neurologic disease. MedGenesis'​ lead program, glial cell-line derived neurotrophic factor (GDNF), is a potentially disease-modifying treatment for Parkinson's disease that has recently completed Phase 2 clinical studies. The program is the first to use MedGenesis'​ proprietary intermittent convection-enhanced delivery (CED) paradigm for targeted, local drug administration to the affected brain area.

Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.

MerLion Pharmaceuticals - We are a bio-pharmaceutical company focused on the development of novel antibiotics to combat the evolving threat of bacterial infections in humans and animals. MerLion Pharmaceuticals is located in Berlin-Buch, Germany and manages the non-clinical and clinical development as well as active pharmaceutical ingredient and drug product development and manufacturing. Our pipeline includes the antibiotics finafloxacin and friulimicin.

At midge medical, we're reimagining the way healthcare systems work. We create the future of diagnostics by making medical testing available to everyone. midge medical is developing diagnostic devices based on blood and other body fluids that are so easy to operate that they can be used by consumers as well as by health care professionals. The complete digitization of the testing procedure is at the core of our vision. We believe testing should be available, accessible and affordable to all. With our aim for ubiquitous testing, we will create a healthier world, reduce infections and take the pressure off public medical resources. Legal imprint: https://cutt.ly/midgeimprint Privacy policy: https://cutt.ly/midgeprivacy

For over 30 years, Miltenyi Biotec has been a major provider of products and services that drive biomedical research and boost cell and gene therapy. More than 4,700 employees in 23 countries combine excellence in research with innovative products to create cutting-edge solutions that make cancer and other disease history. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. At Miltenyi Biotec, scientists, engineers, software developers and many other professionals work together to improve human health by providing smarter cellular technology solutions to researchers and clinicians worldwide.

Mindpeak's mission is to enable personalised cancer treatment through AI tissue diagnostics Our partners are leading pathology and university labs. Our team consists of world-class industry experts in machine learning and company building. Mindpeak's Impact The demand for medical image analysis is growing rapidly but the number of cancer experts remains the same - this results in growing workloads per specialist. We help cancer experts meet this challenge. We build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Our tools assist cancer experts in providing reliable and reproducible diagnoses. This frees specialists from tedious, repetitive tasks such as quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable.

MLM Medical Labs is a leading specialty and central laboratory with comprehensive research services and diagnostic capabilities in Europe and the United States. Offering standard and fully customizable analytical and logistics services across a variety of therapeutic areas, we add value at every stage of the drug development process, from nonclinical and preclinical through phase IV clinical trials. Each therapeutic area is supplemented extensively by different models and batteries of in vitro and ex vivo analyses, offering answers to your therapeutics’ effect on over 900+ parameters while accelerating your research programs. With our strong reputation for scientific expertise, passionate approach to customer care, and adherence to quality data, we empower clients ranging from emerging biotech to Top Ten Global Pharma companies to reach confident clinical decisions that ultimately serve to improve patient lives.

MODAG focuses on research and development of therapeutics and diagnostics for neurodegenerative diseases. It is a privately held company located at the Hochtechnologiepark Wendelsheim, Germany with additional Research & Development facilities in Munich and Göttingen. MODAG’s innovative approach offers a unique combination of early diagnosis and targeted disease-modifying therapies for severe neurological disorders. MODAG´s collaborations with top-tier US and European research institutions, combined with the interdisciplinary research and development expertise of the founder´s and the management team, provide ideal conditions for the accelerated implementation into clinical applications. Built upon an extensive portfolio of patented active compounds, MODAG is developing a new oligomer modulator for Multiple System Atrophy (MSA) and other synucleinopathies such as Parkinson´s disease (PD) with the potential to deliver novel disease-modifying, first-in-class drugs with the potential to halt progression.

MN-AM offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and R&D programs. Founded in 1997, the technology and knowhow of MN-AM is utilized worldwide in more than 150 major industrial, governmental and academic discovery laboratories as well as in regulatory agencies to design and optimize chemical products and to support the safety and risk assessment process. The product portfolio of MN-AM comprises a variety of software and database applications in the area of computational toxicology and chemoinformatics ranging from unique knowledgebases of expert QC'ed in vivo and in vitro toxicity information to in silico predictions of chemical, physical, biological and toxicological properties of chemical compounds including their reactivity and metabolic fate. Members of MN-AM share expertise in molecular informatics, chemometrics, computational modeling and analysis and statistical design of experiments. The MN-AM software development team has extensive experiences in systems development for internationally-funded projects, including private and public projects such as Seurat-1 COSMOS, IMI (eTOX, iPiE), IMI 2 (eTRANSAFE), and Horizon 2020 (ONTOX). MN-AM is also an experienced partner to develop custom-designed solutions suited to the partner's specific needs and has a unique expertise and technology to analyse and model proprietary chemical and biological data.

Molzym is a developer and manufacturer of innovative products for molecular microbiology and microbial pathogen diagnostics. Products range from pre-analytical kits for the enrichment and extraction of microbial DNA to analytical PCR kits with ultra-clean DNA-free reagents and are distributed in more than 30 countries worldwide. MolYsis™ is Molzym's proprietary technology of human DNA removal and targeted isolation of microbial DNA from a variety of liquid and tissue samples including whole blood, CSF, BAL, joint aspirates, tissue biopsies, abscesses and other materials. Molzym's ultra-clean PCR and real-time PCR assays, targeting the 16S/18S genes, allow detection, even at low amounts, and identification down to species level with subsequent sequencing. In addition, Molzym offers CE IVD-marked solutions for the culture-independent detection of pathogens in clinical diagnostics. Manual DNA isolation can be accomplished with SepsiTest™-UMD and with Micro-Dx™ the process is performed fully automated on the SelectNA™plus instrument. It combines highest technical advances with demands for contamination-free and low-hands-on processing of samples. This together with the extremely active broad-range PCR or Real-Time PCR followed by sequencing analysis enables the sensitive detection and identification of pathogens. Learn more about microbial enrichment, manual and automated solutions, molecular diagnostics and NGS and get an inside view on Molzym - read our blog at https://www.molzym.com/molzym-blog.

Your new teammate in the lab! Our lab platform takes over tedious and error-prone manual tasks in 3D cell culture, aiming to replace animal studies. A standardised repository of protocols lets you set up new experiments within minutes. Our AI-based quality control provides real-time transparency on the state of your cell culture, allowing you to worry less and make well-informed decisions.

MSAID transforms the way scientists analyze proteomics data. MSAID is a bioinformatics spin-off from the Technical University of Munich, Germany and is located at the high-tech-center gate, which is part of the TUM campus in Garching. The company was founded by an interdisciplinary team of scientists with the vision to provide better computational solutions to the field of proteomics. The team has an exceptionally strong track record and long-standing expertise in the acquisition, analysis, and interpretation of proteomic data. Our ambition is to replace current algorithms for proteomics with powerful, AI-based solutions, thereby paving the way for a smarter, deeper, and more reliable way of interrogating proteomic data. Legal Notice: https://www.msaid.de/legal-notice

multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform on the basis of the founding scientists'​ (Professor Gabriele Multhoff, Dr Claus Botzler) discovery that cell surface-bound Hsp70 is uniquely expressed on a large proportion of cancers (~50-75%), but not on healthy cells. This makes this form of Hsp70 an excellent and broadly-applicable molecule on which to base the development of innovative therapeutics and diagnostics (theranostics). Based on its discovery of membrane Hsp70, multimmune has succeeded in developing a powerful pipeline of cancer therapeutics. ENKASTIM allows, for the first time, a unique and specific activation of human natural killer (NK) cells which are programmed to recognise and kill cancers expressing membrane Hsp70 via the release of a cytotoxic molecule called granzyme B. These cells destroy tumors and metastases that are invisible to the cell killing (cytolytic) consequences of more conventional T cell-based immunotherapies. Hsp70-expressing tumors can also be targeted using therapeutics based on a unique monoclonal antibody which can detect the membrane form of Hsp70. multimmune's lead diagnostic candidate is the patented and CE-marked Hsp70-exo enzyme immunoassy (ELISA) which detects lipid-associated Hsp70 in the peripheral circulation, levels of which can be used to detect the presence of tumors expressing membrane Hsp70, as well as monitoring therapeutic response and disease recurrence.

MyoPax uses its proprietary muscle stem cell technology to develop advanced regenerative therapies and fight the devastating consequences of muscle diseases. MyoPax is a spin-off from Charité Universitätsmedizin and Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association.

For 20+ years, Nanion combines exceptional instrumentation with trusted scientific support, to accelerate successful drug development and scientific discoveries. As a leading provider of automated patch clamp systems with a wide range of throughput capabilities and formats, we have expanded our product range to in vitro systems for membrane pump/transporter, bilayer recordings, contractility and cell analytics measurements. By sharing our decades of scientific expertise, we aim to become your valued partner, bringing best practice and know-how to accelerate your research. Want to know more? Visit our website or send us an email!

NanoTemper Technologies is deeply committed to the best customer experience. Central to this is a strong focus on high quality products made in Germany that enable researchers to easily, efficiently, and accurately perform protein characterization. With a broad offering of systems, software and consumables for evaluating binding affinities and protein stability, scientists in pharmaceutical, biotech or academic labs will find an optimized workflow, quality results and responsive customer support. Work with a deeply experienced and globally operating team, and realize the NanoTemper experience.

Navigo Proteins discovers and develops novel scaffold proteins-based affinity ligands for commercial biologics GMP purification or as biopharmaceutical drugs/binders. They are all small, stable, highly engineerable, selective, and economically, homogeneously producible. In PRECISION CAPTURING a protein A-like scaffold serves for an antibody-like capture step even of non-Fc bearing molecules. In PRECISION TARGETING human ubiquitin is the basis for highly selective Affilin® ligands as part of a broad range of biopharmaceutical drugs. Navigo Proteins’ unique protein engineering expertise is the basis a world-wide unique, versatile scaffold proteins platform. Our robust, rapid and reliable high-throughput-based, robotics assisted platform designs, produces, analyzes and selects suitable affinity ligand proteins, optimized for their tasks in industrial downstream processing or as biopharmaceutical drugs. PRECISION CAPTURING creates custom ligands against any biologic, Fc-independent, and enables antibody-like affinity downstream processes, with competitive binding capacities, caustic stabilities, usage-cycles, flow rates and commercially available off-the-shelf leaching assays. It is applicable for purifying any recombinant protein, mAb, virus, VLP, cell, etc. Navigo Proteins has established partnerships worldwide to convert its custom affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing. Our PRECISION TARGETING platform creates tailored ligands which bind any desired biologic in biopharmaceutical or in diagnostic use, e.g. radiopharmaceuticals, Protein-drug-conjugates, CAR-T ligands or theranostics, in which the same Affilin® binder is employed in diagnosis, treatment and treatment-monitoring. Navigo Proteins is about 50 heads strong, steadily growing and based in Halle, S/W of Berlin. We offer our expertise to interested pharma, biotech and life sciences companies. https://www.navigo-proteins.com/imprint

neoplas med GmbH was founded in 2009 as a spin-off of the Leibniz Institute for Plasma Science and Technology e. V. (INP) in Greifswald, Germany. Based on the INP research into plasma medicine, the emerging company develops innovative products for medical applications. The first product developed on this basis is the CE-marked kINPen® MED atmospheric pressure plasmajet, the first internationally approved and marketed plasma jet for the treatment of chronic wounds and pathogen-induced skin disorders. It is the result of a long-lasting cooperation with the INP institute, the university hospital of Greifswald, Germany, the Charité hospital of Berlin, Germany, and various industrial partners.

Innovation for you! With two decades of experience, NIPPON Genetics EUROPE stands at the forefront of life science and biotechnology innovation. Based in the heart of Europe, we're your global partner in delivering cutting-edge, high-quality products designed to meet the unique needs of the life science sector. Our extensive product lineup is at the cutting edge of technology, featuring instruments such as Real-Time PCR systems, Gel Documentation systems, and spectrophotometers. We're particularly proud of our newest breakthrough: the FastGene® FAS-X Gel Documentation System. Built with our Blue/Green LED technology, it has been honored with the German Innovation Award 2024! But that's not all—we also offer a comprehensive range of reagents for DNA and protein electrophoresis, PCR, cell biology, and more. Our best-selling Bambanker™, a serum-free cell cryopreservation medium, is trusted by researchers worldwide. At NIPPON Genetics EUROPE, we pride ourselves on our exceptional quality standards, customer benefits, and reliability. With a distribution network in over 70 countries, we're dedicated to helping you achieve your scientific goals. Interested in our products or exploring collaboration opportunities? Have a look at our website: https://www.nippongenetics.eu/ or reach out to us at info@nippongenetics.de.

NMI TT Pharmaservices is a Contract Research Organization dedicated to provide experts services to customers in Pharma, Biotech and Academia. Our business is focused on high-quality services and R&D support, for preclinical drug discovery & development, drug mode of action studies, predictive toxicology, safety pharmacology, and biomarker screening. Our main competences are - Protein Profiling Services - Custom Cell Services - Electrophysiology Services NMI TT GmbH, a privately-held company founded in 2002, is a subsidiary of the NMI Natural and Medical Sciences Institute at the University of Tübingen, a private research foundation, with operations in Reutlingen and Berlin, Germany.

Noah Labs develops AI-based software solutions for medical care and research to facilitate diagnosis, manage conditions, and guide intervention.

Noscendo GmbH, a Duisburg (Germany) based molecular diagnostics company, changes the way infection causative microbes are identified. Introducing a paradigm shift using proprietary algorithms and software harnessing next generation sequencing of cell free nucleic acids isolated from patient samples Noscendo brings the concept of liquid biopsy into the field of infectious diseases. Noscendo’ s software solution is capable of differentiating infection from non-infectious signals and thereby aiding intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.

At Nostos Genomics, we partner with genetic testing labs to turn data into genomic insights and give more people with genetic diseases a fast and clear diagnosis. Over 300 million people live with a rare genetic disease and for most, the journey from the first symptoms to a diagnosis takes more than 5 years. Even after that, diagnoses are often incorrect, and many people end up not being diagnosed at all. Now, new technology is allowing millions to benefit from genetic testing for diagnosis, while at the same time targeted therapies for previously untreatable disorders are being developed. But the last step in genetic testing – interpreting mutations – remains laborious and costly. It can take a genetic testing lab weeks to interpret data from a single patient. Because of limited understanding of the consequences of mutations, the test results are often inconclusive and leave 70% of people undergoing a genetic test without diagnosis. Our CE-certified platform leverages a unique combination of machine learning and synthetic biology to characterize mutations at scale and automate the interpretation. By offering it to labs, we enable them to diagnose more people in a fraction of the time.

Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first water-free technology worldwide for ophthalmology products. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye disease. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye disease. NOV03 and CyclASol® are the two late stage development compounds. NOV03 is the first drug developed to treat evaporative DED associated with meibomian gland dysfunction in a highly effective way. CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of aqueous deficient DED. Both compounds have shown superior clinical benefit, with an onset of action and an excellent tolerability profile. NovaTears® water-free eye drops for dry eye disease have CE certification and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.

NOXXON is a biopharmaceutical company that specializes in drug development in the healthcare sector.

Founded in Europe with more than 40 years of experience, NUVISAN is a fully integrated contract research and development, and manufacturing organization (CRO/CDMO) that offers unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain. NUVISAN, a formerly independent, family-owned contract research organization (CRO), has grown significantly over the years and has expanded its services and capabilities to meet the changing needs of its clients. Operating under the name NUVISAN since 2010, ALS Limited, the global leader in testing, acquired NUVISAN on April 1, 2024, forming the most advanced drug discovery and development organization and providing solutions across continents. We are pleased to offer the following portfolio of services: • Target Identification and Validation • Target-to-Lead • Lead-to-Candidate • Preclinical • Clinical Our services can be provided as stand-alone or integrated solutions and can be customized to your project. To find out more, visit us: www.nuvisan.com or send an email: hello@nuvisan.com.

OMEICOS Therapeutics has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat mitochondrial dysfunction, inflammatory, cardiovascular and other diseases. Epoxyeicosanoids activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. The currently active PMD-OPTION Phase 2a clinical study is evaluating OMEICOS’ lead development program OMT-28 in patients with Primary Mitochondrial Disease.

Omiqa is a contract research organisation, specialising in providing efficient bioinformatics solutions to support life scientist. Our expertise spans from conducting cutting-edge research and developing large-scale bioinformatic workflows to creating custom graphical web and desktop applications.

oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.

The cell-screening you know, now made affordable! With Oncolead you can easily test your compounds over 80+ of human cell-lines in a four-weeks time. We have run our processes for more than 75+ projects in cooperation with big pharma, and we aim to bring our services even to the smallest lab around the world. We know how to do cell-screening and deliver reliable, reproducable and fast results, and we do it with a transparent and competitive pricing model.

No more data siloes. No more missed connections. Advanced chemical search and analysis made accessible to all. Unlock and extract insight for life sciences and chemistry. OntoChem enables your teams to consolidate and normalize all internal and external data from knowledge scattered across different documents, systems and geographical locations. OntoChem is part of Digital Science. Visit our website at ontochem.com

ORGENTEC Diagnostika based in Mainz, Germany, is a diagnostics company, focused on automation of laboratory tests in the fields of autoimmunity and infectious diseases. Enzyme linked immunosorbent assays (ELISA), immunoblots and immunofluorescence assays are "made in Germany" - with research and development, production and distribution from Mainz to over 100 countries.

Origenis - We cure diseases with novel small molecule drugs where no drugs have been discovered yet. We create synergistic small molecule drug pipelines.

Orthogen AG is a privately held, research-based biotech company, founded in Düsseldorf, Germany. Orthogen has developed patented medical platform technologies that are standardized and simple to use for targeted therapies in the field of autologous and regenerative medicine.

We are a German biotech company with a dis­­­­tinctive strategy to fight cancer. Our three academic cancer projects have demonstrated clinical proof of concept and are ready for final development by pharma.

Helping people maintain or regain their freedom of movement – this is Ottobock’s mission. Just as it has been for over 100 years. Our med-tech company continually sets new standards in the fields of prosthetics and orthotics. In 1997, we launched the C-Leg, the world’s first leg prosthesis to be controlled completely by microprocessors. Our C-Brace mechatronic orthosis, which helps people to stand and walk again when they are affected by paralysis due to neurological conditions such as multiple sclerosis and strokes, still features absolutely unique technology. And our portfolio also features wheelchairs and exoskeletons. The latter relieve strain for people who do physically demanding jobs and make workplaces in the industrial, logistics and trade sectors more ergonomic. Tech, digital, human – Ottobock creates an integrated approach by combining innovative products with customised treatment. The company has over 240 of its own patient care centres worldwide, ensuring close relationships with users and providing key momentum for the improvement of existing solutions and the development of new ones. As we move forward with the digitalisation of the fitting process, we are boosting efficiency and making our treatment more comfortable – for external orthopaedics companies and medical supply companies as well. We have maintained a stable growth track for many years, and our sales topped the one billion mark for the first time in 2019. Our over 8,000 employees worldwide contribute to achieving this. We coordinate our international activities from our headquarters in Duderstadt, Germany. Thanks to a global network of research, production and logistics sites as well as sales and service companies in over 50 countries, we combine a genuine international approach with a local presence. Data Privacy, Imprint, Legal Terms - Visit www.ottobock.com/socialmedialinks 

Developing therapeutics to elevate egg quality for IVF success.

Our Mission: Reduce operational risks in areas of applied biomedical science where research results have direct or indirect commercial value and have an impact on competition. Improving pre-clinical Research Quality by introducing standards to applied research will enhance robustness and trust in scientific theories. More importantly, this will also smoothen the way from excellent scientific hypotheses to increased clinical efficacy. By assessing and accrediting quality in pre-clinical research, we expect a reduction in clinical failure rates, and thereby, saving of valuable resources.

Pantherna Therapeutics is a privately held mRNA therapeutics company developing novel first-in-class therapies for indications with high unmet medical need. Pantherna’s development programs are based on two innovative and proprietary PTX platform technologies, offering robust mRNA expression constructs (PTXmRNA) and lipid nanoparticle (LNP) delivery vehicles (PTX_LNP) for localized expression of therapeutic proteins. PAN004 is Pantherna´s first development candidate derived from this platform, representing a defined mRNA-LNP formulation for selective mRNA delivery and expression of a Tie2-agonist in the vascular endothelium of the lung. Pantherna strives for expanding its pipeline with various novel mRNA-LNP candidates enabling the therapeutic use of mRNA beyond the vascular endothelium in distinct tissues such as skeletal muscle or immune cells.

Paul-Ehrlich-Institut is a healthcare regulatory agency that oversees pharmaceuticals, approves vaccines, conducts biomedical research, and protects public health.

Penumbra is a medical devices company that specializes in neurovascular products and healthcare technology.

PEPperPRINT is an innovative biotech company from Heidelberg, Germany, and the leading provider of high density peptide and protein microarrays for antibody characterization or the fingerprint analysis of antibody responses from biological samples. The product and service portfolio was recently complemented by T cell epitope mapping and monitoring, making PEPperPRINT a one-stop solution provider for the fingerprint analysis of immune responses e.g. for epitope mapping, antibody biomarker discovery or the analysis of adverse immune effects. PEPperPRINT’s peptide microarrays and screening services have been used by researchers around the world with over 200 peer-reviewed publications.

Siemens Healthineers is a leading medtech company with over 125 years of experience. We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Our portfolio, spanning in vitro and in vivo diagnostics to image-guided therapy and cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the greatest challenges in healthcare. We will continue to build on these strengths to help overcome the world's most threatening diseases, enable efficient operations, and expand access to care. We are a team of more than 71,000 Healthineers in over 70 countries passionately pushing the boundaries of what is possible in healthcare to help improve the lives of people around the world.

Phyton Biotech is the world's leader in pharmaceutical plant cell fermentation (PCF®) technology. A global supplier of high quality oncology actives via PCF, our products are registered in every major country in the world. With state-of-the-art facilities near Hamburg and Vancouver, we also offer comprehensive development services via PCF for plant-based actives, complex small molecules, and a variety of products used in the treatment of cancer and other serious illnesses.

Imagine a world without chocolate. Horrifying, right? But the supply of cocoa is endangered and chocolate is as bad as meat for our planet. We make future-proof chocolate using precision fermentation. Doing this, our chocolate is 10x more sustainable and 20% cheaper than conventional chocolate. In order to mimic the organoleptic properties of chocolate (tender, smoothly melting taste release) we are working on the flavor itself but also on replacing the cocoa butter. 55 Mio lbs of chocolate are consumed every day. By 2035 we will substitute a big chunk of it through our sustainable chocolate.

PlasmidFactory GmbH, based in Bielefeld, Germany, is the leading contract manufacturer of plasmid and minicircle DNA. The company offers the production of plasmids and minicircles in several quality grades: Research Grade and ccc Grade for research purposes and pre-clinical applications, High Quality (HQ) Grade as starting material for e.g. GMP production of RNA and viral vectors and GMP Grade for clinical applications. PlasmidFactory has its own separate, dedicated HQ production area with new laboratories to produce highly purified plasmid DNA. To avoid cross-contamination, only one plasmid per time is produced there. Besides production of individual plasmids and minicircles, In Stock products that are deliverable immediately off the shelf, are also provided: e.g. reporter genes (gfp, lacZ, luc), AAV Helper & Packaging vectors (pDG/pDP family, several serotypes) or pEPI plasmids (containing S/MAR elements). PlasmidFactory is working on several research topics – some in close co-operation with industrial and academic partners.

We at PL BioScience are experts in cell culture supplements derived from human Platelets. Our mission is to enhance the advances in cellular research and therapy with one forward-looking Technology: ELAREM™. The ELAREM™ Platform unites tailored cell culture supplements based on Human Platelet Lysate. The human origin combined with a rich growth factor content not only supports cell growth, but also enables various applications: The products cover all needs of cell expansion in academic research, pre-clinical research and cellular therapy. This ensures seamless transitions in regenerative medicine – from lab to patients in need. Our story goes back to 2015 and the idea to deliver animal component-free cell culture supplements. Today, we have changed the possibilities of cell expansion: Researchers switch from Fetal Bovine Serum to our animal suffering-free products. Stem Cell Therapy benefits the regeneration potential of our platelet-derived products. And we keep moving forward. Let's create the future of cell expansion together and join us on our mission.

Priavoid is a clinical stage drug development company based in Düsseldorf, Germany. Its therapeutic focus is on protein misfolding disorders in the area of neurodegeneration. Key component of Priavoid's technology is an anti-oligomeric or anti-prionic mode of action, that efficiently and effectively disassembles neurotoxic aggregates by using all-D-peptides.

ProBioGen is a renowned contract development and manufacturing organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines. Our additional new building houses 1000 L single-use bioreactor capacity to keep up with the ever-increasing demand from our clients. A second 1000 L single-use bioreactor is coming soon. With 30 years of experience in animal cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end. Watch & learn more: https://youtu.be/vtEgrEVfj70

Our commitment to scientists is to support them in making new scientific discoveries and groundbreaking research within the life sciences and gene therapy. It is our underlying mission, to help progress new therapies safely, quickly and affordably, so together we can provide solutions to people suffering from poor health and affected by disease every day. PROGEN is made up of a team of experts within AAV and the life sciences and is partnered with gene therapy experts worldwide. We are more than just a manufacturer of antibodies, proteins and ELISAs kits. We strive to understand what scientists need, so we can create solutions and ultimately deliver high quality antibody and exclusive AAV products, which solve your research challenges within academia, biotech and pharma, and ensure PROGEN can continue to be a trusted and reliable partner. Visit our website www.progen.com Imprint: https://bit.ly/3uEZf2h Privacy Statement: https://bit.ly/3dMSgxm

Transforming proteins into pioneering drugs ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and delicate small molecules into pioneering drugs. ProJect Pharmaceutics adds value to client´s bio-pharmaceutical products by applying an innovative concept of development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized formulations and delivery systems for biologics that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products, biosimilars as well as "bio-betters" are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing. We offer: • predictive formulation analytics • formulation development including in-depth protein analytics • lyophilization process development and optimization • lyophilization in dual chamber prefilled syringe • development of liposomal formulations, producible by simple stirring • manufacturing of preclinical study material • technology-transfer including scale-up to GMP-manufacturer We deliver: • optimized formulations for biopharmaceuticals • tailored manufacturing processes and transfer to GMP manufacturing • development reports ready for submission to the authorities for registration

ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms. Our deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk’s unique capabilities in vector safety, integration site analysis, and bioinformatics were added to our portfolio, establishing ProtaGene. Our combined protein- and gene-based analytical platforms make it the leading analytic service provider across the biopharmaceutical and gene and cell therapy development spaces. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.

Proteo Biotech is a biotechnology company that focuses on developing next-generation preventive therapeutic technology using a pioneering tissue-protective drug.

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Our mission: Develop and manufacture highly effective wound dressings for acute wounds suchs as burns, abrasions, lacerations, skin graft donor sites chronic wounds Our main focus is on burn wounds Products & solutions for medical personnel (wound dressings, cooling vests) Our high quality products are developed & manufactured in Germany Strong international network of burn and plastic surgeons Our products distributed in more than 25 countries Our R&D: New projects in close collaboration with leading specialists

Rapid Micro Biosystems is an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. We are the trusted partner in quality control microbiology automation, enabling our customers to improve and save lives. This vision has been realized with the development of the Growth Direct® System. Our Growth Direct® platform automates and modernizes the antiquated, manual quality control microbiology testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line QC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. Our company values guide us in our vision: Customer Driven – We are committed to providing our customers with the highest quality products and services Respect – We welcome and embrace our differences to create a trusting environment Grit – We are determined to turn challenges into successes. One RMB – We operate as one team, committed to our shared purpose. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands.

About ratiopharm ratiopharm became known as the first generics company in Europe. Today, ratiopharm is a pharmaceutical brand with a broad portfolio of OTC and generic prescription medicines in several European countries. Including Germany, Austria, Spain and Finland. ratiopharm - a brand of Teva Since 2010, ratiopharm has been part of Teva Pharmaceuticals, a global leader in generics and biopharmaceuticals. As part of Teva, we benefit from access to innovative networks and high-quality, internally produced active ingredients. Access to medicines and health Every day, we work to ensure access to medicines and thus the supply of essential medicines to millions of people. We provide high-quality generics for nearly all indications and therapeutic solutions that are customized to the needs of our patients. We are convinced that quality can be offered at fair prices. And that not only helps individuals, but also makes a sustainable contribution to the performance and efficiency of the healthcare system.

Refoxy Pharma is a pre-clinical stage biotechnology company developing medicines for the treatment and prevention of aging and aging-associated diseases.

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, including advanced therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA and Stevenage, UK. In 2024, the company joined the United Nations Global Compact, emphasizing Rentschler Biopharma’s focus on sustainability.

Repairon's mission is the development, the manufacturing and the commercialization of induced pluripotent stem cell (iPSC) based tissues for organ repair. Our lead product are contractile heart tissue patches – Engineered Human Myocardium (EHM) – for the treatment of patients with advanced heart failure.

Rommelag is the inventor of blow-fill-seal technology (BFS) and the global market leader in the aseptic filling of liquids and semisolids with its bottelpack machines. Our machines are primarily used in the pharmaceutical, chemical, and food industries. Together with our customers, we develop innovative packaging solutions tailored precisely to the specific packaging task at hand. We built the first prototype bottelpack machine in 1962. Since then, we have continued gathering and sharpening our expertise in packaging solutions using BFS. We are delighted to say we now have customers in over 80 countries worldwide and more than 2,000 dedicated employees.

ROTOP Pharmaka is a leading German pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.

ROXALL Group is an international pharmaceutical company based in Hamburg, Germany. Our core business is pharmaceuticals for allergen immunotherapy – the only causal allergy therapy renowned by the World Health Organization (WHO) that not only has the capacity to prevent an allergy turning into asthma but can also block the growth of new sensitizations. At ROXALL, we strive to constantly improve our treatments and to manufacture the highest quality products. As a result, we have made several and many of the most important innovations in this field. ROXALL Group has subsidiaries in Europe, Asia and Latin America. The acquisition of the allergy-line of a pharmaceutical company in Bilbao, Spain, opened us a solid basis for future growth. Research in immuno- therapy has been the main focus of this company for more than 70 years. Our team in Bilbao works closely with leading research institutes, providing us with greater potential for developing new treatments. In addition to our allergen immune therapies, our subsidiary company DR. BECKMANN Pharma offers medical products that help ease many allergy symptoms. Our products range from nasal showers and ointments for sensitive skin to high quality allergen encasings and peak-flow meters.

Ruhr University Bochum is a Higher Education institution that offers research programs and academic degrees.

Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers simplify progress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are part of the solution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. Based in Göttingen, Germany, Sartorius also has a strong global reach with more than 60 production and sales sites worldwide. We regularly expand our portfolio through the acquisition of complementary technologies. In 2024, Sartorius generated sales revenue of around 3.4 billion euros. Currently, more than 13,500 employees from around 110 nations are working for customers around the globe.

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout your project: Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. Technical Expertise: Our team provides unmatched proficiency in your proteomic analysis endeavors. Customized Solutions: We provide customized solutions to meet your specific research needs. Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report. Our Platform Is Used For: • Protein Biomarker Identification and Verification • Novel Drug Target Discovery • Mode-of-Action Analysis • Pathway Activity Analysis • Disease Model Characterization, among other key applications Join us on our mission to revolutionize medicine! #PrecisionMedicine #Proteomics

SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases.

Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company addressing high unmet medical needs in the areas of immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies for challenging or currently undruggable targets. With over 15 development programs focusing on targets in indications where antisense-based approaches have clear benefits over other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.

[INTRODUCING OUR COMPANY] The people of Seegene are on a purposeful mission to improve the world we live in. We aim to improve the quality of life for everyone globally by bringing molecular diagnostics to the masses. Molecular diagnostics is the most effective method to accurately diagnose ailments and is also the best way to diagnose them early which is when you can make the most difference in the recovery treatment. With industry-leading IP in molecular diagnostics reagent assays, we are dedicated to leveraging our unique technologies to increase our product portfolio, expand our market coverage, and lowering the total cost to serve our customers so that molecular diagnostics become a part of the fabric of everyone’s life and thus, improving the quality of life for everyone in the world. [OUR HISTORY AND OUR FUTURE] Since our founding in 2000, we have been steadfastly focused on molecular diagnostics. Currently, our product portfolio consists of over 250 molecular diagnostics reagent kits as well as a wide range of instruments and consumables that are sold globally. Testament to our expertise, when the pandemic started, Seegene was one of the first companies in the world to provide testing kits that were crucial in the fight against COVID. Today, we are a company with revenue of over $1 billion dollars and 65% gross margins. With 8 overseas entities, we generate a majority of our revenue outside of Korea. In keeping with our spirit of innovation and making a difference in the world, there are many exciting innovations being worked on at Seegene which will make it easier for the world to access the benefits of molecular diagnostics. We are transforming our business from a discrete reagent assay and instruments business to a platform business that will create new markets for molecular diagnostics and improve the quality of life for everyone. We hope that you will join us in our mission to make a meaningful difference in the world.

Headquartered in Burlington, MA, for 40 years SEKISUI Diagnostics has been committed to helping improve the lives of patients by providing innovative medical diagnostics to physicians and laboratories. We continue to invest in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems, and have a leading position as a provider of rapid tests in the US and high throughput coagulation systems in Japan. Our workforce spans six sites located in four countries. We are a sister company to SEKISUI Medical in Japan, making us a worldwide company with R&D and Manufacturing facilities on three continents. We develop, manufacture, and supply billions of tests each year to the global healthcare market through our commercial networks and partners. Our product lines include: • Clinical chemistry reagents • Coagulation reagents • Point-of-care rapid tests and immunoassay system • Enzymes and specialty biochemicals

SensID is specialized in the design and manufacturing of Reference Material for DNA diagnostic procedures. Our reference material is manufactured under the highest standards in the world. The products are especially designed and suitable for R&D, Validation, external control, preparation of accreditation processes, round robin tests, as part of your diagnostic device or kit and whatever you can imagine. We provide: gDNA, cfDNA/ctDNA, cfDNA/ctDNA in Plasma, FFPE tissue and slides with defined allelic frequency and 100% defined sequence, defined mixing ratio of wt/mut cells and more for use in PCR, Sequencing, or any application you can imagine. For further information, please contact us under: info@sens-id.com

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE´s immunoassays.

We drive RNA research with tailored molecular tools. We are from Munich and provide researchers with highly complex & advanced genetic tools. Our core expertise is RNA interference, bioinformatics, and RNA research tools for RNA-Seq and Ribo-Seq. Distinguished by their exceptional targeting specificity and efficiency, our gene function analysis tools include - siPOOLTM for reliable gene silencing, raPOOLTM for targeted RNA affinity purification and riboPOOLTM for efficient ribosomal RNA depletion. Our technology combines high complexity oligo pooling (“Pack Hunter” approach), proprietary design algorithms, and quality production to achieve highly precise and rapid results. siTOOL’s reagents are used by Pharma for target discovery and validation and are mentioned in a growing list of academic publications. Comprised entirely of scientists, siTOOLs provides outstanding technical support and offers bespoke experimental and bioinformatic services, making it a favoured research partner for accelerating scientific discoveries and drug development.

At SOMATEX®, we are dedicated to improving healthcare by providing high quality solutions every day. For more than 25 years, we have brought new products and technologies to the world, especially in the fields of breast care, soft tissue and bone marrow biopsy, pulmonary interventions, fetal therapy, assisted reproduction and radiation protection. Thanks to exceptional innovations, we have set new standards in women's health. We are committed to meet the needs of patients, clinicians and practitioners to enable better diagnostics and therapies and improve the standard of care. Today, SOMATEX® products are used around the world in university clinics, hospitals, breast centers and medical practices to continuously improve the quality of patients' life. Our growth is driven by the strength of our research and development capability, highly qualified employees that share our vision and values, and our strong network of partners. For more information visit our website: www.somatex.com

SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. SphingoTec GmbH was established in 2002 by Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the "gold standard" sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).

sterna biologicals is a clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as atopic dermatitis, ulcerative colitis, asthma and chronic obstructive pulmonary disease (COPD). By targeting GATA-3, a key master transcription factor that plays a central role in chronic inflammatory diseases, the company’s proprietary DNAzyme-based drug candidate, hgd40, antagonizes several inflammatory processes and mediators. sterna biologicals has completed multiple phase IIa clinical trials with hgd40 in a number of commercially attractive chronic inflammatory diseases with high unmet medical need. If you are interested in partnering with us, please reach out at partnering@sterna-biologicals.com.

STRATEC designs and manufactures fully automated analyzer systems, software and smart consumables for its partners in the fields of clinical diagnostics and life sciences. Building on an unparalleled breadth of technology and the expertise gained in more than forty years of automating laboratory processes, STRATEC has established itself as one of the world's leading providers of automation solutions for in-vitro diagnostics and life science companies. Worldwide partners can rely on STRATECs first class solutions and thereby share responsibility towards their customers and patients. STRATEC covers the entire value chain – from development to design and production through to quality assurance. The company's success is based on the talents and skills of the employees and their commitment to always perform the extraordinary. All partnerships are built on mutual trust, continuity and professionalism. For STRATEC, partnership means responsibility, passion and commitment, to both the customers and the products, that goes well beyond the duration of the product life cycle. Imprint: www.stratec.com/imprint Privacy Policy: www.stratec.com/privacy-policy

The highly experienced research team founding the STRATIFYER Molecular Pathology GmbH has developed techniques to analyze routine tumor material for sophisticated molecular analysis. A specialized process has been developed that guarantees fast and reliable assessment of prognostic and predictive gene signatures in mid-throughput fashion. This technology has been exploited for multiple years to enable in-depth genomic research accompanying large clinical trials. First pathology labs have been powered by STRATIFYER Molecular Pathology GmbH to integrate RNA expression profiling tests in clinical routine. The molecular STRATIFYER test systems shall enable physicians to optimize anti-cancer treatment at patient's initial diagnosis according to individual differences of the tumors.

Symrise develops, produces and sells fragrance, flavoring and food ingredients, cosmetic active ingredients and raw materials as well as functional ingredients and solutions that enhance the sensory properties and nutrition of various products. With a market share of 12 % (2024), Symrise is one of the world's top suppliers in the F&F market. The company’s approximately 35,000 products are mainly produced on the basis of natural raw materials like vanilla, citrus fruits, onions, fish, meat, blossoms and plant materials. Its flavors, substances, perfume oils and sensory solutions are often central functional components for its customers’ end products. These customers include manufacturers of perfumes, cosmetics and foods, the pharmaceutical industry and producers of nutritional supplements, pet food and baby food. The company has two segments: Taste, Nutrition & Health and Scent & Care. The Taste, Nutrition & Health segment is built around Food & Beverage, Pet Food and Aqua Feed. The Taste, Nutrition & Health segment uses its combined expertise as well as scientific research to offer customers and partners unique, natural ingredient-based and sustainable solutions in the areas of taste, nutrition and health. The Scent & Care segment breaks down into the Fragrance, Cosmetic Ingredients and Aroma Molecules divisions. They produce and sell fragrances, cosmetic ingredients, aroma molecules and mint aromas. The segment has sites in more than 30 countries and markets over 16,000 products in 135 countries. The combination of the segments Taste, Nutrition & Health and Scent & Care sets us apart from the competition. Through it, we offer our customers a unique portfolio, work in innovative segments and tap new markets.

SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy of cancer.

SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates. SYNLAB operates in 30+ countries across four continents. More than 27,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.

At Systasy, we accelerate the development of effective treatments by deepening our understanding of disease mechanisms. Our proprietary barcoding technology enhances every stage of the drug discovery pipeline, from target identification to patient stratification, utilizing hyper-multiplexed pathway screens and patient-derived models. Systasy's AI-supported platform excels in generating high-quality data for patient stratification and biomarker discovery. Additionally, our cutting-edge DNA barcoding technology empowers viral vector developers with unparalleled precision in understanding the biodistribution and cell-type-specific infectivity of multiple viral serotypes at once, fundamentally transforming healthcare.

Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical need

Founded in 2000, TauroPharm GmbH is a German company specialising in medical devices with antimicrobial efficacy. As TauroLock™ solutions have been recommended in expert guidelines, we continue to expand our global network.  Our mission  TauroPharm aims to make the application of vascular access devices (VAD) easier and safer. We are developing more effective ways to prevent catheter-associated complications – ranging from blood clotting to fatal infections. Improving the patient's quality of life remains our number-one priority.  Our products  We have created a range of lock solutions suitable for implanted central-venous catheters (CVC) and port systems. These products contain several ingredients to prevent catheter occlusion and catheter-related infections. Today, TauroLock™ solutions are recommended in interdisciplinary guidelines on a national and international scale. These include the ESPEN (European Society for Clinical Nutrition and Metabolism), GAVeCeLT (Italian association for long-term central-venous access devices), SFNCM (French Society of Clinical Nutrition and Metabolism), and DGfN (German Society of Nephrology). All TauroLock™ products have been investigated in clinical trials and are certified by regulatory bodies.  Our sales network  To distribute our products, we collaborate with international partners who provide support and advice to customers in their respective countries. Our correspondents have been carefully selected and hold trust-based partnerships with healthcare professionals in nephrology, oncology, gastroenterology, intensive and palliative medicine, and home care.   Our educational programmes  TauroPharm offers special training in all countries where TauroLock™ products are sold and implemented. These programmes help distributors familiarise themselves with our lock solutions and their application. Privacy policy: https://www.wonderlink.de/@tauropharm

T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.

Serving ~1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer's imaging equipment or PACS system, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights.

tiakis biotech AG, formerly Proteo Biotech AG, located in the north of Germany, is the next generation preventive therapeutic technology company based on its clinical stage pioneering tissue protective drug 'Tiprelestat', which is identical to a human recombinant anti-inflammatory protein. The company is fully dedicated to its novel therapy approach to treat life-threatening unmet medical need diseases. Our approach represents a paradigm shift towards a preventive approach by e.g. protecting against inflammatory organ damage and failure following invasive major surgery, by offering the potential for reversing the vascular pathology of pulmonary arterial hypertension or by prevention of serious disease progression of COVID-19.

TIB Molbiol is a medium-sized biotech company based out of Berlin, Germany who has supplied the global market for over 30 years with reagents for research and medical diagnostics. We were recently bought by Roche, one of the largest pharma and biotech companies in the world. Roche has committed to keep the start -up character of the company so that the company can benefit from the advantages of a small biotech and the muscle and power of a large pharma/biotech company such as Roche. Our customers are mainly diagnostic and research labs, servicing patients every day, selecting from any of our more than 2,500 diagnostic kits and LightSNiP assays. We fulfill many special orders for custom design of individual assays, for patient need.

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results. NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.

TolerogenixX vision is to innovate Immunosuppression with its newly developed MIC Cell Treatments. MIC Cell Treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Transplant - and Autoimmune Disease Patients. TolerogenixX has been able to generate strong pre-clinical as well as clinical data in the indications of Transplantation and Autoimmune Diseases e.g. SLE since its foundation in 2016.

Topas Therapeutics is a clinical-stage biotechnology company transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology. Our antigen-coupled nanoparticle platform harnesses the tolerogenic power of the liver to treat autoimmune diseases. Our proprietary Topas Particles Conjugates target liver sinusoidal endothelial cells, a specific type of antigen-presenting cells highly effective at inducing T cell tolerance. With a technology adjustable to a broad spectrum of disease-relevant antigens, we have established a growing and advanced clinical pipeline to induce systemic tolerance. To learn more visit https://topas-therapeutics.com/

Transimmune AG is leading a revolution in dendritic cell therapy having uncovered how dendritic cells are made physiologically in vivo.

Treamid Therapeutics GmbH was founded in 2016 with the aim to develop new and innovative treatments for respiratory and inflammatory diseases. All our small molecules are under global patent protection. Our aim is to develop new drugs in the area of high unmet need for respiratory and inflammatory disease, supporting patients with new innovative and easily accessible medications. We are collaborating with well-renowned institutions and CROs in different fields of our research and development. We also have our own in vitro lab driving our research and developing new methods to further investigate our molecules in different disease areas.

TRiCares GmbH is a medical device company based in Munich, Germany, with additional offices in Paris, the U.S., and Brazil. Founded in 2013, the company specializes in minimally invasive solutions for tricuspid regurgitation (TR), a serious heart valve condition affecting millions of patients. TRiCares focuses on transcatheter tricuspid valve replacement (TTVR) systems, aiming to meet the clinical need for non-surgical treatments. The flagship product, Topaz, is a transfemoral TTVR system designed for easy implantation via the femoral vein. It features a dual-stent design that accommodates anatomical variability and is suitable for high-risk patients, avoiding the need for open-heart surgery. TRiCares is actively conducting clinical trials in the U.S., Canada, and Europe to further validate the effectiveness of the Topaz system. Recently, the company raised $50 million in Series D financing to support its clinical milestones and expand its market presence.

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Decoding RNA modifications to revolutionize cancer and inflammation treatment. Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapeutic molecules to modify tRNA and target cancers and inflammatory diseases.

Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists within the German Mammography Screening Programme, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to. Vara’s full-stack platform manages all processes within a screening centre and makes breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.

VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation. Through biochemical and technological innovation, we strive to transform the way antibodies and antibody-drug conjugates (ADCs) are created to develop more effective and safe therapies for patients. With our transformative technologies, we can streamline and derisk early bioconjugate development. We have established a rich pipeline of proprietary ADCs and are collaborating with a number of partners to provide access to our unique research & development capabilities going from target to antibody to ADC.

Who are we? vermicon AG from Munich, Germany, specializes in the development and production of sustainable solutions for the industrial microbiology. Since 1997, our actions are guided by the credo that the conventional limitations of microbiology have to be broken down in order to receive convincing solutions. Successful answers for microbiological challenges and a permanent implementation of these solutions into practice is what we strive for. What are we offering? PRODUCTS Detection systems and test kits for industrial customers. Handy and suitable for on-site application, fast and nevertheless highly specific results. Simple workflow. Microbiology in a standardized and industrialized shape. SERVICES
 Comprehensive analyses for microbiology – fast, reliable and flexible. Our technology allows us to deliver insights and results that cannot be achieved with conventional methods. MICROBIOLOGICAL CONSULTING 
A unique combination of microbiology and consulting. Break new ground with us! Even for national or international research projects, we are your reliable partner. We bring our great wealth of experience to bear in every new project and every new problem. A broad spectrum of technological options and a high innovative capacity guaranteed by a team of microbiologists and chemists allow us to always break new and exciting ground. Learn more about us – our corporate principles say it all: ...to provide unique and efficient solutions for microbiology ...to meet successfully microbiological challenges which no one has solved before.

We turn active ingredients into medicine. As one of the leading pharmaceutical service providers for the aseptic manufacture of injectable medicines, we are a global player – and a family business. Together with our 6,000 employees, we help improve the lives of people around the world. We combine tradition and innovation in a job that has meaning. Ravensburg is where our roots are. We make a significant contribution to reliably supplying patients with medicines from our state-of-the-art production sites in Europe and the United States. We work hand in hand with pharmaceutical and biotechnology companies of all sizes, accompanying them on their journey to help those who are affected with their treatment of cancer, multiple sclerosis, and other diseases – from active ingredient development all the way to its delivery in people. With success comes responsibility. Teamwork, openness, and commitment: These qualities are important to us. At Vetter, we are sustainably helping to shape the future. We fully support personal and professional development – to build a strong team in which everyone can develop their skills, and in which every contribution counts. And for those who rely on us. Find out more about our company at www.vetter-pharma.com/ Privacy Notice: https://www.vetter-pharma.com/en/privacy-notice Imprint: https://www.vetter-pharma.com/en/imprint

Vibalogics is a viral vector CDMO that offers a unique understanding of virotherapy for high quality and resource-efficient delivery.

ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At ViGeneron we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms. ViGeneron will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders.

INSPIRED BY DEDICATION - that was our credo right from the start and we want to live up to this claim in the future as well! For more than four decades now, Virion\Serion has proven to be a reliable, competent and trusted partner for our customers worldwide. All processes, services and products are managed in accordance with the EU directive 98/79/EG, under a certified quality management system according to DIN EN ISO 13485, to ensure and maintain the highest quality of our products and services. All products are manufactured in Wuerzburg and distributed worldwide.

We provide innovative gene editing reagents, screening services and engineered model systems for the global R&D market. Our success is based on the proprietary 3Cs technology.

Vivoryon is focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The mechanisms of action underlying our approach enables us to target a variety of disease areas with high medical need. With historic roots in diabetes research and development as well as neurodegenerative disorders, Vivoryon’s focus is now on applying our approach to developing medicines in inflammatory and fibrotic disorders.

We are a leading player and one of the world's most research-intensive chemical companies. Our range of highly developed specialty products extends from silicones and polymeric binders and additives for a number of different industrial sectors, to bio-engineered pharmaceutical actives (biologics), and hyperpure silicon for semiconductor and solar applications. As a technology leader focused on sustainability, we promote innovations with high value-added potential. Our goal is to ensure a better quality of life for you and future generations – through health care, energy efficiency and protection of the climate and environment. Disclaimer: http://bit.ly/li-disclaimer

Xell is a Germany-based biotech company that develops, produces and markets media and feed supplements for gene therapeutics and vaccines.

XO Life stands for - a state-of-the-art platform solution for long-term Patient Insights from the real world - real time information exchange between patients and pharma - all-in-one platform to be used across all treatments and indications We are a young and dynamic eHealth company setting a new standard patient data collection through scientifically based questionnaires across all treatments and medications. XO Life helps the pharmaceutical industry to better understand its patients. Our goal is to make digital treatment monitoring and patient feedback the gold standard in R&D, marketing and sales, while ensuring the highest data protection and security standards.

YUMAB Company profile The German biotech company YUMAB was founded in 2012 as spin-off the University of Braunschweig. In little more than five years, YUMAB (a phonetic play on “HUMAB”, which stands for “human monoclonal antibody and in which the “Y” symbolizes the well-known antibody structure) has become a global player in human monoclonal antibody (mAb) development, and drives the general trend in the immunotherapy space toward the use of fully human mAbs for therapeutic applications. The YUMAB® antibody platform provides rapid, reliable and robust development of “state-of-the-art” and “next-generation” fully human antibodies. The technologies base on more than 28 years of continuous research and development of our founders, who are well recognized scientific experts in the field of recombinant antibody technologies and who have an outstanding track-record in academic and industrial research. YUMAB provides optimized antibody development solutions for: i) discovery & development of novel, fully human antibodies, ii) antibody engineering & humanization, and iii) personalized & custom libraries Key features of the YUMAB® platform are: i) world’s best, naturally derived, universal, human antibody libraries (>10e11) ii) powerful in vitro selection technologies including on-cells-selection for difficult targets iii) large scale screening platforms iv) comprehensive portfolio of antibody engineering & humanization technologies v) compatibility to all therapeutic antibody formats YUMAB provides fee for service solutions with attractive pricing and flexible license models & options as well as collaborative projects. YUMAB’s research & development unit performs internal pipeline and partnered projects ranging from the development of novel antibody therapeutics to the discovery to novel targets technologies. Our mission is to make the best human antibody technologies available for the early development to accelerate translation of research from bench to bedsite.